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Exogenous lipoid pneumonia: an important cause of interstitial lung disease in African 
infants 
Background and objective: To describe the clinical-radiological-pathological characteristics and 
treatment outcomes of childhood exogenous lipoid pneumonia (ELP) and elucidate oil 
administration practices. 
Methods: A retrospective study of children with histologically-confirmed ELP at Red Cross 
Children’s Hospital, South Africa. Caregivers were interviewed to understand oil administration 
practices.  
Results: Twelve children of Zimbabwean heritage aged 2.1-10.8 months were identified between 
2012 and 2017.  Repeated oral administration of plant-based oil for cultural reasons was reported 
by 10/11 caregivers. Cough (12/12), tachypnea (11/12), hypoxia (9/12) and diffuse alveolar 
infiltrates on chest radiography (12/12) were common at presentation. Chest computed 
tomography revealed ground glass opacification with lower zone predominance (9/9) and 
interlobular septal thickening (8/9). All bronchoalveolar lavage specimens appeared cloudy/milky, 
with abundant lipid laden macrophages and extracellular lipid on Oil-Red-O staining and 
documented polymicrobial (6/12) and Mycobacterium abscessus (2/12) co-infection. Antibiotics, 
systemic corticosteroids and therapeutic partial lung lavage were interventions in all, 8 and 5 
patients respectively. Median time to clinical resolution was 1.1 months IQR (0.5-8.0) with 
radiological resolution only in 2/12 cases.  
Conclusions: Paediatric ELP resembles pulmonary alveolar proteinosis. Health workers should 
explicitly probe for a history of oil administration in children with non-resolving pneumonia and 




CHAPTER 1: INTRODUCTION 
1.1 Context 
Exogenous lipoid pneumonia (ELP) is a disorder caused by inhalation or aspiration of mineral, 
plant-based or animal-based oils that is generally considered uncommon(1, 2). Lipoid pneumonia 
related to the use of nonvolatile oils in children has been reported in the literature in several parts 
of the world. One of the earliest articles published on this condition was based on autopsy findings 
in Canadian children who developed pneumonia following nasopharyngeal injections of oil in 
hospital(3). Subsequently, literature on lipoid pneumonia related to medical use of oil-based 
products in children as well as the use of various folk remedies involving nasal or oral 
administration of these oils in children and related cultural practices have also been documented(1, 
4, 5). 
 
In addition to a history of oil ingestion or aspiration, children with ELP have been reported to 
present with non-specific clinical and radiologic findings and variable treatment outcomes(1, 2). 
Expert reviews provide a consensus approach of discontinuing oil, treating infections and 
identifying underlying risk factors(1) however to the best of our knowledge, no formal systematic 
reviews and meta-analyses have been conducted. Systematically reporting on the global context 
of non-accidental ELP in children with regard to clinical-radiological-pathological characteristics 
and treatment outcomes may provide a holistic perspective with a robust evidence base for 
management of these children. 
 
1.1.1 Methodological aspects 
This study was registered on PROSPERO, an international prospective register for systematic 
reviews as CRD42017068313 and detailed methodology published online. We included studies 
conducted in any context globally involving children less than 18 years old suspected to have 
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ELP, suspected under the following conditions:1) history of oil administration related to time of 
presentation/diagnosis, 2) clinical presentation of persistent or recurrent unexplained pneumonia 
associated with hypoxia or tachypnea, 3) radiological evidence of persistent diffuse alveolar 
infiltrates on chest radiograph or computed tomography (CT) chest, and/or 4) 
histological/cytological findings on bronchoalveolar lavage (BAL) or lung biopsy that were 
consistent with exogenous lipid content. Studies that had adults along with children were included 
if the data on adults could be separated and excluded. Letters, editorials, commentaries, 
conference abstracts, all types of reviews, meta-analyses, non-human studies and non-English 
studies were excluded.   
 
We employed a multi-concept Boolean search strategy based on the Population, Intervention, 
Control, Outcome, Timing and Setting (PICOTS) framework(6). This search strategy used 
keywords related to ELP in children and was restricted to English publications published within 
the last 50 years. This period was arbitrarily deemed to represent data that was currently relevant. 
The first author systematically searched Pubmed, EMBASE, Web of Science, SCOPUS, CINAHL 
and the Cochrane Library to identify studies describing ELP in children published from 1967 to 
December 2017. The Pubmed search strategy used was: ("child"[MeSH Terms] OR Child[tw]) OR 
("infant"[MeSH Terms] OR infant[tw]) AND ("pneumonia, lipid"[MeSH Terms] OR 
("pneumonia"[All Fields] AND "lipid"[All Fields]) OR "lipid pneumonia"[All Fields] OR 
("exogenous"[All Fields] AND "lipoid"[All Fields] AND "pneumonia"[All Fields]) OR "exogenous 
lipoid pneumonia"[All Fields]) AND (1967:2017[dp]) AND "English"[la]. The primary reviewer 
screened abstracts for eligibility, retrieved full texts to confirm eligibility and extracted data for 
quantitative synthesis. Using a standardized tool, the first author independently extracted data 
from eligible articles and consulted senior reviewers during this process whenever required. 
Specific information recorded from each study included and details on study quality assessment 
are provided as supplementary material. (Technical Appendix) 
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We identified 1,259 articles through the electronic database search and one additional record 
through hand search of references in the current literature. Duplicates were excluded and of the 
remaining 1,104 titles and abstracts, 153 were eligible for full text assessment. Of these, 43 
studies were included for qualitative synthesis as depicted in the PRISMA flow chart (Figure 1).  
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Additional records identified 
through other sources  
(n = 1) 
Records after duplicates 
removed  
(n = 1103) 
Records screened  
(n = 1104) 
Records excluded  
(n = 951) 
1. Studies were not in humans (14) 
2. Reviews (41) 
3. Conference abstracts/editorials (14) 
4. Studies did not include children (18) 
5. Related to ELP but non-English (27) 





 Full-text articles 
assessed for eligibility  
(n = 153) 
Full-text articles excluded with reasons  
(n = 110) 
1. Not specific to ELP (57) 
2. Participants details also published among 
included studies (10) 
3. Accidental/iatrogenic ELP (40) 
4. Insufficient information to describe as 
ELP (3) 
Studies included in narrative synthesis  
(n = 43)  
1. Suspected ELP without histological assessment (11/43) 
2. Possible ELP with suggestive histological assessment but no mention of lipid staining (4/43) 
3. Probable ELP with lipid staining on histology/cytology but no mention of extracellular lipid on 
BAL/frozen section lung biopsy (14/43) 
4. Confirmed ELP with lipid staining on histology/cytology plus mention of extracellular lipid on 
BAL/frozen section lung biopsy (12/43) 
5. Confirmed ELP with lipid staining on histology/cytology plus mention of extracellular lipid on 
BAL/frozen section lung biopsy and additional fat analysis (2/43) 
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A narrative summary for the studies eligible for this systematic review is provided classified 
restricted to non-accidental etiologies. Majority of the studies included were case series and case 
reports, thus summary measures could not be pooled together nor could quantitative data be 
consolidated in a metanalysis. 
 
1.1.2 Summary 
In the past half-century, paediatric ELP resulting from non-accidental etiologies, predominantly 
cultural practices, continued to be documented in Asia, the Americas and Europe. However 
published data from Africa and Australia are lacking. Furthermore, the trend in reporting studies 
of paediatric ELP has been decreasing over the last five decades, with the highest peak of 
published articles noted between 1987 and 2006. Increased awareness of the complications of 
these oil practices may explain this decline over time. Notably, the medical use of Lorenzo’s oil 
and ketogenic diets in children with severe neurological conditions should be recognized as a 
possible albeit rare cause of ELP (7-9). 
 
Figure 2: Global map depicting the number of studies conducted on non-accidental 





Figure 3: Graph depicting the number of studies conducted on non-accidental paediatric 




The type, amount, frequency and duration of oil use documented in the selected studies varied 
widely; and may partly explain the heterogeneous clinical-radiological pattern of paediatric ELP 
that makes it indistinguishable from other causes of persistent pneumonia. Five studies in this 
review reported on NTM infections in children with ELP that resulted in significant morbidity, a 
finding consistent with previous experimental studies (10) and literature in adults(11, 12). Supportive 
management particularly antibiotic treatment is the most common treatment offered to children 
with ELP. Although qualitative findings from this systematic review seem to suggest that steroids 
and lavage may improve time to clinical resolution, surgery could be associated with many 
complications including death, and radiologic resolution may be delayed in comparison to clinical 
resolution, prospective studies to assess the efficacy of treatment interventions in paediatric ELP 
are needed.  
 
Furthermore, the definitions of paediatric ELP are too heterogenous to make comparisons across 
studies. We therefore propose a scale of diagnostic certainty comprising five levels: suspected, 
probable, possible, confirmed on histocytological assessment, and confirmed on both 































standardized case definitions for patient eligibility in future ELP studies. Diagnostic certainty levels 
have been proposed for randomized control trials in other conditions in children such as wheezing, 
where standardized definitions are lacking (13). Additionally, standardized reporting could be 
adapted from international registries such as the international management platform for ChILD(14) 
or any other global registry. Preferably data collection should be prospective to prevent pitfalls of 
bias and missing data.  
 
The main limitations of this systematic review were the studies included comprised case reports, 
case series and few cross-sectional studies making it difficult to pool data; exclusion of non-
English articles; and a single reviewer. Studies reviewed were highly biased with respect to patient 
selection due to the nature of their design. Notwithstanding these limitations, we believe that our 
study provides a current and robust perspective on ELP in children resulting from non-accidental 
aetiologies. This review highlights that paediatric ELP resulting from cultural/medical practices 
continues to be described in Asia, the Americas and Europe. Although clinical-radiological 
patterns vary widely making them non-specific to diagnosing paediatric ELP, health-workers 
should not forget that this is an important cause of ILD in children with persistent pneumonia. 










1.2 Ethical Considerations 
We obtained consent from the University of Cape Town Human Research and Ethics Committee 
(548/2017) to conduct the case series. Additionally, we sought permission from the Red Cross 
War Memorial Children’s Hospital administration for retrospective review of patient records. 
Researchers and interpreters signed a study confidentiality agreement to mitigate against the risk 
disclosure of caregivers’ contact details occurring, accidentally or otherwise. Data captured 
electronically was anonymized, encrypted and stored in databases and devices that were 
password protected to ensure data privacy. The lead researcher, trained in qualitative research 
employed an empathetic approach during the conduct of all interviews and was cognizant of not 
attributing any blame to the caregivers of study participants. To maintain confidentiality, telephonic 
interviews were conducted in a private room with an interpreter if needed, and without audio 
recording participant names. Data were stored in password-protected files with access restricted 













1.3 Author guidelines for Pediatric Pulmonology 
Original Research Articles 
Original Research Articles should follow the standard structure of abstract, introduction, methods, 
results, discussion, and references, and may include up to six tables and/or images when 
appropriate. Original Research Articles should be limited to 3,500 words (not including the 
abstract or references). The abstract should not exceed 250 words, and references should be 
limited to forty (40). 
 
Main Document 
All manuscript types must include a title page, abstract, text and references in the Main Document. 
Standard, double-spaced manuscript format, in 12 point font is requested. Number all pages 
consecutively. 
 
Title page: The title should be brief (no more than 100 characters in length including spaces) and 
useful for indexing. All authors’ names with highest academic degree, affiliation of each, but no 
position or rank, should be listed. For cooperative studies, the institution where research was 
primarily done should be indicated. In a separate paragraph, specify grants, other financial 
support received, and the granting institutions (grant number(s) and contact name(s) should be 
indicated on the title page). If support from manufacturers of products used is listed, assurances 
about the absence of bias by the sponsor and principal author must be given. Identify meetings, 
if any, at which the paper was presented. The name, complete mailing address, telephone 
number, fax number, and e-mail address of the person to whom correspondence and reprint 
requests are to be sent must be included. Keywords should also be noted on the title page. For 
usage as a running head, provide an abbreviated title (maximum 50 characters) on the bottom of 
the title page. 
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Summary/Abstract: In accordance with the structure of the article, with or without separate 
headings, outline the objectives, working hypothesis, study design, patient-subject selection, 
methodology, results (including numerical findings) and conclusions. The Summary should not 
exceed the word counts outlined above. If abbreviations are used several times, spell out the 
words followed by the abbreviations in parentheses. 
 
Acknowledgements: Technical assistance, advice, referral of patients, etc. may be briefly 
acknowledged at the end of the text under “Acknowledgements.” 
 
Informed Consent: Informed consent statements, if applicable, should be included in the 
Methods section. 
 
References/citations: References may be included at the end of your text, or uploaded as a 
separate file. Ensure your references are up to date, and include a critical selection from the world 
literature. References should be prepared according to CSE (Council of Science Editors) citation-
sequence style. Refer to the Scientific Style and Format: The CSE Manual for Authors, Editors, 
and Publishers, 8th edition (University of Chicago Press). Start the listing on a new page, double-
spaced throughout. 
 
Number the references in the sequence in which they first appear in the text, listing each only 
once even though it may be cited repeatedly. 
 
When citing a reference in the text, the style advocated by CSE suggests numbers appear in 
superscript and appear before punctuation marks (commas or periods). In the citation-sequence 
system, sources are numbered by order of reference so that the first reference cited in the paper 
is 1, the second 2, and so on. If the numbers are not in a continuous sequence, use commas (with 
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no spaces) between numbers. If you have more than two numbers in a continuous sequence, use 
the first and last number of the sequence joined by a hyphen, for example 2,4,6-10. 
 
In the references, list the first ten authors of the cited paper. If there are more than ten authors, 
list the first 10 authors followed by 'et al'. 
 
Journals’ names should be shown by their abbreviated title in Index Medicus. 
 
Manuscripts in preparation or submitted for publication are not acceptable references. If a 
manuscript “in press” is used as a reference, a copy of it must be provided with your submission. 
 
Sample references: 
Standard journal article 
Landau IL, Morgan W, McCoy KS, Taussig LM. Gender related differences in airway tone in 
children. Pediatr Pulmonol 1993;16:31-35. 
Book with authors 
Voet D, Voet JG. 1990. Biochemistry. New York: John Wiley & Sons. 1223 p. 
Book with editors 
Coutinho A, Kazatch Kine MD, editors. Autoimmunity physiology and disease. New York. Wiley-
Liss; 1994. 459 p. 
Chapter from a book 
Hausdorf G. Late effects of anthracycline therapy in childhood: evaluation and current therapy. 
In: Bricker JT, Green DM, D'Angio GJ, editors. Cardiac toxicology after treatment for childhood 
cancer. New York: Wiley-Liss; 1993. p 73-86. 




Keywords: On the title page, supply a minimum of 3 to 5 keywords, exclusive of words in the title 
of the manuscript. A guide to medical subject heading terms used by PubMed is available 
at http://www.nlm.nih.gov/mesh/MBrowser.html 
 
Abbreviations: Define abbreviations when they first occur in the manuscript and from there on 
use only the abbreviation. Whenever standardized abbreviations are available use those. Use 
standard symbols with subscripts and superscripts in their proper place. 
 
Drug names: Use generic names. If identification of a brand name is required, insert it in 
parentheses together with the manufacturer’s name and address after the first mention of the 
generic name. 
 
Eponyms: Eponyms (diseases or biologic entities named for persons) should not be used when 
standard descriptive terminology is available. Examples include club cells (formerly known as 
Clara cells); and granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis). 
It is permissible to use the eponym in parenthesis at the first mention of the term in cases in which 
the eponym is still in common use. 
 
Formatting Specific to Original Research Articles: Divide article into: Title Page, 
Summary/Abstract, Introduction, Materials and Methods, Results, Discussion, and References, 
starting each section on a new page. All methodology and description of experimental subjects 
should be under Materials and Methods; results should not be included in the Introduction. Please 
ensure the following appears in the appropriate section of your manuscript: 
• a concise introductory statement outlining the specific aims of the study and providing a 
discussion of how each aim was fulfilled; 
• a succinct description of the working hypothesis; 
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• a detailed explanation of assumptions and choices made regarding study design and 
methodology; 
• a description of the reasons for choosing the type and number of experimental subjects 
(patients, animals, controls) and individual measurements; if applicable, information about 
how and why the numbers may differ from an ideal design (e.g., the number required for 
achieving 90% confidence in eliminating Type II error); 
• specifics about statistical principles, techniques and calculations employed and, if 
applicable, methods for rejecting the null hypothesis; 
• a concise comparison of the results with those of conflicting or confirmatory studies in the 
literature; 
• a brief summary of the limitations of the scientific methods and results; and 
• a brief discussion of the implications of the findings for the field and for future studies. 
Tables 
Tables should not be included in the Main Document but submitted as a separate DOC or RTF 
file. Number tables with Arabic numbers consecutively and in order of appearance. Type each 
table double-spaced on a separate page, captions typed above the tabular material. Symbols for 
units should be used only in column headings. Do not use internal horizontal or vertical lines; 
place horizontal lines between table caption and column heading, under column headings, and at 
the bottom of the table (above the footnotes if any). Use footnote letters (a, b, c, etc.) in consistent 
order in each table. All tables should be referred to in the text. Do not submit tables as 
photographs and do not separate legends from tables. 
 
Images 
Image files must be submitted in TIF or EPS (with preview) formats. Do not embed images in the 
Main Document. Number images with Arabic numbers and refer to each image in the text. The 
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preferred form is 5 X 7 inches (12.5 X 17.5 cm). Print reproduction requires files for full color 
images to be in a CMYK color space. 
 
Please note authors are encouraged to supply color images regardless of whether or not they are 
amenable to paying the color reproduction fees. Color images will be published online, while 
greyscale versions will appear in print at no charge to the author. See Author Charges below. 
 
Journal quality reproduction requires grey scale and color files at resolutions yielding 
approximately 300 ppi. Bitmapped line art should be submitted at resolutions yielding 600-1200 
ppi. These resolutions refer to the output size of the file; if you anticipate that your images will be 
enlarged or reduced, resolutions should be adjusted accordingly. 
 
Lettering on images should be of a size and weight appropriate to the content and the clarity of 
printing must allow for legibility after reduction to final size. Labeling and arrows on images must 
be done professionally. Spelling, abbreviations, and symbols should precisely correspond to 
those used in the text. Indicate the stain and magnification of each photomicrograph. Photographs 
of recognizable subjects must be accompanied by signed consent of the subject of publication. 
Images previously published must be accompanied by the author’s and publisher’s permission. 
Image legends should be brief and included as a separate DOC file under the heading: “Image 
Legends.” When borrowed material is used, the source of the image should be shown in 
parentheses after its legend, either by a reference number or in full if not listed under References. 
 
Online Supporting Information 
Additional non-essential material such as text, appendices, tables, images, video, and soundtrack 
files may be submitted for posting as supporting information to an article. The scientific value of 
such material should be evident. The material should be submitted simultaneously with the 
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manuscript so that it may undergo peer review. In naming these files, please note the file names 
should be preceded by the letter “E.” For example “E-table 1,“E-image 1,” “E-text,” etc. 
 
Note that supporting online material is not typeset, nor proofread following the review process, so 
please ensure the material is accurate and free of typographical errors. Supporting material 
should be prepared in the same manner as the print material. 
 
While supporting information does not appear in the print version, a notation is made that 
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pneumonia and consider the diagnosis of ELP in settings where this is a common 67 





















Introduction  87 
Exogenous lipoid pneumonia (ELP) is considered a rare disorder caused by inhalation or 88 
aspiration of mineral, plant-based or animal oils(1, 2). It results from a foreign body type of 89 
inflammatory reaction due to the presence of lipid material in the lung parenchyma 90 
initiating cellular and humoral defense mechanisms(3, 4). Populations at risk include the 91 
elderly, children, and those with an underlying swallowing dysfunction or 92 
neurological/neuromuscular disorder resulting in an unprotected airway. Additionally, 93 
forced ingestion in the recumbent position in infants and young children who actively 94 
refuse oil may result in gagging and aspiration of the oil(5, 6). Common ailments for which 95 
oil has been used for both medical and cultural practices include constipation, colic, and 96 
nasal stuffiness(7).  97 
 98 
Paediatric ELP resulting from non-accidental etiologies, mainly cultural practices, has 99 
continued to be documented in Asia, the Americas and Europe in the past half-century. 100 
There is a dearth of published data from Africa. Moreover, there has been a downward 101 
trend in reporting studies of ELP in children during this time period. Oil administration may 102 
be a common practice that is not recognised to be potentially dangerous by caregivers or 103 
medical professionals. A history of this practice may  not be forthcoming from caregivers 104 
unless health workers probe for it explicitly, leading to misdiagnosis, treatment delay and 105 
a missed opportunity to prevent ongoing oil aspiration(8). The aim of this study was to 106 
describe the clinical-radiological-pathological pattern of ELP in children in the South 107 





Following ethical approval from the University of Cape Town Human Research Ethics 111 
Committee (548/2017), we conducted a retrospective case series and investigated oil 112 
administration practices in study participants at Red Cross War Memorial Children’s 113 
Hospital, a tertiary referral hospital serving the Western Cape province of South 114 
Africa.   115 
 116 
Participant selection 117 
We consecutively selected children aged < 18 years with cytohistologically confirmed ELP 118 
defined under the following conditions: 1) clinical presentation of persistent or recurrent 119 
unexplained pneumonia associated with tachypnea or hypoxia; 2) radiological evidence 120 
of persistent diffuse alveolar infiltrates on chest radiography or computed tomography 121 
(CT) chest; 3) extracellular lipid and lipid laden macrophages in bronchoalveolar lavage 122 
(BAL) and/or frozen section lung biopsy and/or a; 4) history of oil administration related 123 
to time of presentation/diagnosis. There were no exclusion criteria for the retrospective 124 
aspect of the study which was descriptive reporting based on standard of care. 125 
 126 
Study procedures  127 
Permission to search patient records including medical folders and contact information 128 
was obtained from the hospital management. We sought a waiver of consent for these 129 
patients as their data was anonymised in this phase of the study. The lead researcher 130 
 
 
reviewed medical records of eligible patients and extracted relevant clinical data which 131 
included socio-demographic characteristics, clinical findings, laboratory results and data 132 
relating to treatment and outcomes. Data were captured electronically, anonymised and 133 
recorded in a standard case report form.  134 
 135 
The study radiologist and pathologist independently reviewed and entered data related to 136 
chest radiography, CT findings, bronchoalveolar lavage (BAL) and lung biopsy findings 137 
respectively. Children with suspected interstitial lung disease (ILD) routinely underwent 138 
high resolution CT utilising a paediatric friendly radiation dosing protocol with controlled 139 
ventilation if under the age of six years. Flexible bronchoscopy (OlympusR 2.8 mm) and 140 
BAL was performed in all children under general anesthesia through a laryngeal mask. 141 
Sites for BAL were informed by prior radiology findings. Histocytological assessment of 142 
BAL and lung biopsy specimens routinely include Oil Red O stain for lipids, Periodic acid 143 
Schiff stain for glycoprotein exudates, Perls’ Prussian Blue stain for iron, Grocott’s 144 
methanamine silver stain for fungi and Ziehl-Neelsen stain for acid fast bacilli. Processing 145 
and examination of BAL and lung tissue were conducted according to the European 146 
Management Platform for Childhood Interstitial Lung Disease protocols(9). 147 
 148 
Partial therapeutic lung lavage (using 2.8 mm OlympusR flexible bronchoscope) with 200- 149 
300 ml 0.9% warmed saline, targeting the worst affected regions of the lung, was 150 
performed in selected cases where clinically significant hypoxemia and/or symptoms did 151 
not resolve spontaneously with medical management and cessation of oil administration 152 
in hospital. Given the limited evidence available for this therapeutic modality, treatment 153 
 
 
was individualized, and sub-optimal response judged clinically by the pulmonologist. 154 
Repeated therapeutic lavages were also performed, if the patient’s symptoms and signs 155 
persisted despite a prior lavage. 156 
 157 
The lead researcher contacted caregivers of identified participants and conducted 158 
interviews telephonically or in person to elucidate oil administration practice information. 159 
Verbal or written informed consent was obtained from caregivers who agreed to 160 
participate in this component of the study. Detailed qualitative methods, emergent themes 161 
and selected quotes are available. (E-text)  162 
 163 
Analyses 164 
Quantitative data around clinical-radiological-pathological characteristics and treatment 165 
outcomes of children suspected with ELP were analyzed using STATA version 15.1. 166 
Continuous variables were described using medians and interquartile ranges. Categorical 167 
variables were described using proportions. Qualitative data around oil practices related 168 
to ELP in children from in-depth analysis of narratives powered for information(10) were 169 
transcribed, manually coded, synthesized into themes and managed using ATLAS.ti 170 
software.  171 
 172 
Results 173 
Clinical characteristics  174 
Between October 2012 and December 2017, we identified twelve children with ELP as 175 
per our study case definition. All children were of Zimbabwean heritage, presenting in 176 
 
 
infancy (median age 4.0 months, range 2.1-10.8). Cough was the main presenting 177 
symptom in all children with a duration varying from 1 day to 3 months. Common 178 
symptoms at presentation of these infants included: tachypnea (11/12), hypoxia in room 179 
air (9/12), fever (4/12), air trapping (2/12) and digital clubbing (2/12). Six out of 12 children 180 
were hospitalised for pneumonia on at least one other occasion besides the episode in 181 
which the diagnostic BAL done provided histocytological evidence of ELP. Underlying risk 182 
factors that were documented included gastro-oesophageal reflux (GOR) confirmed on 183 
scintigraphy (3/6), and in combination with silent aspiration confirmed on contrast swallow 184 
(2/4). (Table 1) 185 
 186 
Details of oil administration 187 
A history of oil administration was obtained from caregivers prospectively in seven out of 188 
12 patients once the clinical pattern was recognised. In the remaining 5, the history of oil 189 
administration was confirmed retrospectively. Ten of the 11 mothers interviewed 190 
confirmed the administration of oil to their children. This emerged to be a nearly universal 191 
cultural practice by Zimbabweans, even in the Cape Town diaspora.  192 
 193 
One of the 11 mothers interviewed denied a history of oil administration. She however 194 
acknowledged that she had heard of this practice from other Zimbabwean caregivers 195 
while in the hospital. Notably her child was left under the care of the child’s paternal 196 




Two children in this case series were siblings [ID-03 and ID-07]. All caregivers with more 199 
than one child also confirmed giving oil to their other children (7/10). The younger sibling 200 
to child [ID-01] was hospitalised for pneumonia at the age of 6 weeks. His mother stopped 201 
oil administration at the age of 2 months following our team’s advice during the preliminary 202 
phase of this study. On a follow-up telephone call, the infant was reported to be 203 
asymptomatic at the age of 6 months, and BAL was not done.  It was noted that the elder 204 
sibling to child [ID-08] also received oil and developed respiratory symptoms like his 205 
brother but died at the age of 3 months with a respiratory illness. (E-text) 206 
 207 
Radiological characteristics 208 
Plain chest radiographs were performed on all children. The initial radiographs taken at 209 
the hospitalisation in which a diagnostic BAL was performed showed diffuse ground glass 210 
opacification in all 12 cases. Expansile consolidation predominantly in the right upper lobe 211 
was noted in 2/12. Nine out of 12 children underwent HRCT chest and four distinct 212 
patterns were evident: 1) ground glass opacification with lower zone predominance (9/9); 213 
2) smooth interlobular septal thickening (8/9)/ crazy-paving appearance (5/9); 3) 214 
expansile right upper lobe consolidation (2/9) and 4) fat attenuation within the areas of 215 
airspace consolidation (1/9). These patterns were present in various combinations. 216 




Pathological and microbiological characteristics 219 
Twelve BAL samples and one frozen section lung biopsy [ID-6] were assessed. On gross 220 
inspection, all BAL specimens were cloudy, 11/12 being predominantly milky in nature 221 
(Figure 4). Cytohistological assessment of most specimens revealed an abundance of fat 222 
laden macrophages and large extracellular droplets on Oil Red O staining.  Eight children 223 
had BAL samples with neutrophil predominant type inflammation (median neutrophil 33%, 224 
range 12-88% in those who had cytopsin done). Lung biopsy done in one patient showed 225 
evidence of chronic lymphocytic interstitial inflammation in addition to large extracellular 226 
lipid droplets on the Oil Red O stain of the frozen section. All BAL and biopsy specimens 227 
stained periodic acid Schiff negative, excluding other diagnoses such as pulmonary 228 
alveolar proteinosis. (E-table 1) 229 
  230 
Microbiological evaluation of BAL specimens included bacterial, fungal, mycobacterial 231 
and viral studies. Only 3/12 children had negative BAL specimens on microbiology 232 
assessment; 6/9 were polymicrobial. In two children with normal immunological work up, 233 
Mycobacterium absessus complex was cultured from BAL, both with evidence of 234 
pulmonary disease. The first child [ID-9] presented with persistent right upper lobe 235 
consolidation and pleural effusion. This child had significant underlying comorbidity 236 
including severe GOR and silent aspiration necessitating Nissen fundoplication and 237 
gastrostomy. The second child [ID-11] presented with an expansile pneumonia of the right 238 
upper and middle lobe.  In addition to BAL from multiple lobes, M. abscessus boletti was 239 




Treatment and outcomes 242 
Supportive treatment provided comprised: educating caregivers to stop administering oil 243 
to their children (7/12); oxygen supplementation (11/12) (duration range 5, 71days), non-244 
invasive ventilation including continuous positive airway pressure (8/12) (duration range 245 
1, 27 days) and high flow nasal cannula oxygen (5/12) (duration range 3, 8 days), 246 
mechanical ventilation (1/12); antibiotics (12/12) and systemic corticosteroids (8/12). 247 
Varying corticosteroid regimens including a three-day pulse of intravenous 248 
methylprednisolone in one child, and oral prednisone in seven children administered at 249 
1-2 mg/kg/day for 5-14 days, or longer in the cases on treatment for M.abscessus. All 250 
children on prolonged courses of corticosteroids also received prophylactic 251 
cotrimoxazole. Five patients underwent partial therapeutic lung lavage. Four children 252 
needed only one procedure to obtain satisfactory clinical response and one needed 3 253 
sequential lavages over 11 weeks before achieving satisfactory clinical improvement. 254 
(Table 2) 255 
 256 
The median hospital stay duration was 23 (IQR 6-30, range 2-117) days. Clinical 257 
resolution was documented in 10/12, with a median time to clinical resolution from 258 
presentation of 1.1 (IQR 0.6-8.0, range 0.3-14) months. To date, radiological resolution 259 
on plain radiography from presentation is only documented in two, at 19.4 months and 260 
27.0 months respectively. In the remaining ten children, radiological resolution has not 261 
been documented at 0.8–4.4 months of follow-up. No mortalities were reported and the 262 





Exogenous lipoid pneumonia in children has been widely described in the Middle East, 266 
particularly Saudi Arabia, India and South Korea, as well as Central and South America, 267 
specifically Mexico and Brazil(11-15). To the best of our knowledge, this is the first study 268 
from Africa describing histologically confirmed ELP. Although ELP has been described in 269 
the literature to be uncommon(1, 2), our study reveals that this diagnosis may go 270 
unrecognised if a history of oil administration is not obtained in children presenting with 271 
recurrent/persistent pneumonia or ILD. Furthermore, our study highlights significant 272 
morbidity associated with ELP as reflected by severe disease observed in most cases, 273 
likely from prolonged and repeated oil aspiration.  274 
 275 
All but one of the caregivers interviewed reported that oil administration was a universal 276 
cultural practice among Zimbabweans. Oil was administered to alleviate colic and 277 
constipation, similar to cultural and medical reasons provided from other regions(5, 6, 11, 16). 278 
Only one caregiver denied a history of oil administration. Gupta et al reported that up to 279 
18% of caregivers of children with ELP denied administration of oil to their children(17). 280 
ELP should therefore not be immediately excluded if caregivers deny oil administration at 281 
initial presentation. Although all the children in this series were of Zimbabwean heritage, 282 
our qualitative research findings suggest that oil administration to children occurs among 283 
various local South African cultures, and we could have missed out on these children. 284 
 285 
From a clinical perspective, distinct CT and BAL patterns were identified that are similar 286 
to pulmonary alveolar proteinosis (PAP). The macroscopic milky appearance of BAL and 287 
 
 
finding of extracellular alveolar lipid is key to the diagnosis of ELP. Similar to previous 288 
literature, diffuse ground glass opacification predominantly in the posterior segments, and 289 
interlobular thickening were common patterns on chest CT in children with ELP. Fatty 290 
attenuation within consolidation has also been described in children with ELP, however 291 
we only observed this pattern in one child in our series(15, 18, 19). Interestingly, a unique 292 
pattern of a dense expansile right upper lobe consolidation was noted in two children with 293 
confirmed M. abscessus disease. This radiological presentation has not been typically 294 
described in children with ELP or comorbid nontuberculous mycobacteria (NTM) 295 
infection(13, 20). We postulate that this expansile pattern possibly reflects a severe form of 296 
a lung oleoma/paraffinoma described as a localized lipoid pneumonia due to exogenous 297 
lipid in the alveoli, characteristically seen in adults(18, 21) 298 
 299 
To the best of our knowledge M. abscessus co-infection has not previously been reported 300 
in children with ELP. Other NTMs described in children with ELP include M. fortuitum, M. 301 
chelonei and M. smegmatis(11, 20, 22-24). M. abscessus complex has been previously 302 
described in adult patients with ELP(25-27). In a Japanese study in which M. abscessus 303 
was identified in the sputum sample of an adult with ELP, the NTM was additionally 304 
identified in the mineral oil the patient was ingesting(26). Several authors have postulated 305 
that oil increases the pathogenicity of mycobacteria possibly by hindering macrophage 306 
function and phagocytosis(3, 28). In an animal experiment, Kudoh et al. demonstrated that 307 
there was increased virulence of NTM when inoculated in oil in comparison to aqueous 308 
solutions(29). Similarly, the lipid environment in the lung may be responsible for other 309 
secondary infections detected in BAL cultures among children with ELP(7, 30), also seen 310 
 
 
in this series. Our study suggests that NTM infections in children with ELP are not 311 
uncommon in our context. Health workers should be vigilant for NTM co-infection in 312 
children with ELP and conversely, consider ELP in children presenting with NTM 313 
infections.  314 
 315 
Discontinuing oil, treating infections, identifying underlying risk factors and overall 316 
supportive care in line with consensus reviews, (1, 2, 15, 18) was instituted for children in this 317 
study. Furthermore, we report success in utilising corticosteroids and partial therapeutic 318 
lung lavage as additional treatment strategies for ELP. Therapeutic lung lavage is 319 
frequently employed in the treatment of PAP with the aim of reducing alveolar deposits, 320 
a mechanism of action that would be comparable in ELP and is therefore biologically 321 
plausible. Similar to previously reported studies of ELP in children in Brazil(15, 31), all 322 
children who underwent partial therapeutic lavage in our study showed clinical 323 
improvement, however radiological resolution was delayed. Data to establish the 324 
effectiveness of corticosteroids and therapeutic lavage for ELP are limited(1, 2).  325 
 326 
 We set out to describe a case series of children with histologically confirmed ELP, with 327 
no intention of proving association or determining causation. Incomplete data and recall 328 
bias are potential limitations inherent to our study design. Although aspiration risk was 329 
identified in two cases, it remains unclear why not all children exposed to repeated oil 330 
ingestion develop ELP. Notwithstanding these limitations, we believe the strengths of this 331 
study lie in the multi-method approach to highlighting and understanding the clinical-332 
 
 
radiological-pathological characteristics and oil administration practices associated with 333 
ELP in our context.  334 
 335 
In conclusion, our case series highlights that ELP masquerading as persistent pneumonia 336 
or PAP, is an uncommon but serious condition in our context and may occur anywhere in 337 
the world where similar cultural practices are common. Obtaining a history of oil 338 
administration from caregivers, chest radiography and cytological analysis of BAL are 339 
sufficient to make the diagnosis of ELP. NTM co-infection should be excluded in children 340 
with suspected ELP. Health education messages to highlight the risks associated with the 341 
cultural practice of oil administration are needed.  342 
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Figure 1 (a): Frontal Chest Radiograph: Widespread bilateral ground-glass attenuation 436 
with more confluent right middle and right lower lobe consolidation. Note the apico-basal 437 
distribution of airspace disease and the prominent right basal air-bronchograms.   438 
 439 
Figure 1 (b): High Resolution CT Chest: Widespread areas of ground-glass opacification 440 
demonstrate smooth interlobular septal thickening resulting in the so called appearance 441 
of “crazy paving”. Note the predominant posterior and basal predilection with areas of 442 









Figure 2 (a): Frontal Chest Radiograph:  Confluent expansile consolidation of the right 450 
upper and right mid zone with further patchy left upper lobe airspace disease. Note the 451 




Figure 2 (b): CT Chest (mediastinal settings): Expansile consolidation involving the 454 
posterior segment of the right upper lobe and the superior segment of the right lower lobe. 455 
Note the areas of low attenuation within the areas of consolidation that signify 456 





Figure 3(a):  Frontal Chest Radiograph: Extensive, bilateral ground-glass opacification 460 
with relative sparing of the peripheries and lung bases.   461 
 462 
Figure 3(b): High Resolution CT Chest (mediastinal settings): Posterior airspace 463 
opacification with interspersed areas of low attenuation that registers Hounsfield values 464 





Figure 4 (a): Bronchoalveolar specimen macroscopic appearance: Milky-oily. 468 
 469 
Figure 4 (b): Bronchoalveolar specimen microscopy: Oil Red O staining showing mainly 470 
large extracellular lipid droplets with isolated macrophages.   471 
 472 
Figure 4 (c): Frozen section lung biopsy microscopy: Oil Red O staining showing large 473 
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NPA and/or BAL† 
01β Male 6.1 Sunflower 
oil  
12 months; 
from day 2 of 









02μ Female 9.8 Not 
available 






03§β Male 7.5 Olive oil  14 days; from 
the age of 6 
months; 2.5ml 
orally once daily 
Noneγ  Tachypnea, 
hypoxia 
4.0 Enterovirus†, Human 
Rhinovirus 
04πσ Male 1.4 Mother 
denied 
giving oil 
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hospitalisations 
05α Male 6.2 Plant-based 
‘cooking’ 
oil** 
5 months; from 
day 1 of life; 
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07§β Male 10.8 Olive oil 14 days; from 
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09βλ Male 3.7 Sunflower 
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10α Male 2.1 Sunflower 
oil 
2 months; from 
day 6 of life; 









1 prior LRTI 
hospitalization 
0.1 None 
11π Male 2.6 Olive oil 1.6 months; 
from age of 4 
weeks; 2.5ml 
orally once daily 



































1 prior LRTI 
hospitalization 
BAL, bronchoalveolar lavage; GOR, gastroesophageal reflux; LRTI, lower respiratory tract infection 481 
θMilk scan performed 482 
δContrast swallow performed 483 
ϵSwallowing assessed by speech therapist 484 
γOnly clinical history at BAL diagnosis 485 
*Risk factor history from caregiver qualitative interview 486 
**Plant-based oil including blends of soya bean oil, sunflower oil, canola oil, or unspecified 487 
***‘Fish’ oil is not oil from fish but rather a plant-based oil used for frying fish among other foods 488 
†Infection present in the BAL 489 
μUnable to reach patient on phone or in the community 490 
σChild was left under the care of the grandmother 491 
ρRetrospective diagnosis of ELP, child given oil for an additional 6 months 492 
§Siblings within the case series 493 
αHas sibling/s who also received oil but did not experience respiratory-related complications 494 
βHas sibling/s who also received oil and experienced respiratory-related complications 495 
λSibling death during infancy related to a similar respiratory illness 496 
πHas no siblings 497 
 
 
¥Posterior urethral valves (PUVs) ablated and bladder neck surgically excised 498 






























[number of days 
post-admission] 
Total days hospitalised in the 
diagnostic BAL admission 
Time to clinical 
resolution (months) 
01 23 CPAP (2) Yes (7) Prednisone at 2mg/kg/day (7) Yes (1) [21] 24 8.0 
02 7 None Yes (11) None None 13 0.3 
03 16 None Yes (15) None None 2 0.5 
04 23 CPAP (6) 
HFNC 
(4)   
Yes (14) Prednisone at 1mg/kg/day (14) None 25 12.0 
05 0 None No None None 2 14.0 
06 15 IPPV (1) 
CPAP (1) 
HFNC 
(8)   
Yes (14) Methylprednisone at 10mg/kg/day 
(3) 
None 22 0.6 
07 5 None Yes (7) Prednisone at 1mg/kg/day (5) None 6 1.2 
 
 
08 27 CPAP 
(23) 
Yes (26) Dexamethasone stat; Prednisone 
at 2mg/kg/day (21) 
Yes (1) [19]  
 
30 1.0 
09 71 CPAP 
(27) 
HFNC 




Prednisone commenced at 
2mg/kg/day (94) 
Yes (3) [38; 56; 86] 98 3.2 
10 16 CPAP (2)  Yes (5) Prednisone at 2mg/kg/day (7) Yes (1) [22] 
 
23 0.8 
11 52 CPAP 
(16) 
HFNC 
(7)   
Yes (ongoing) 
M.abscessus treatment¥ 
Prednisone commenced at 
2mg/kg/day, tapered (ongoing)  
Yes (1) [52] 117 3.9 
12 12 CPAP (3) 
HFNC 
(3)   
Yes (5) None None 23 
 
0.8 
NIV, non-invasive ventilation; MV, mechanical ventilation; CPAP, continuous positive airway pressure; HFNC, high flow nasal cannulae; IPPV, intermittent 519 
positive pressure ventilation 520 
§Nebulized Amikacin (underlying renal disease), Intravenous Imipinem, Linezolid and Ciprofloxacin) and oral Azithromycin for 1 month. Then discharged on oral 521 
Linezolid, Ciprofloxacin and Azithromycin. 1-month follow-up BAL was negative on mycobacterial culture.  522 
 
 






















E-table 1: Radiological and pathological findings 543 
Patient 
ID 
Chest radiograph CT chest BAL macroscopic 
appearance  
BAL/Biopsy microscopic 
01 Bilateral ground glass opacification, 
predominantly on the right. Lobar 
distribution more confluent in the 
RUL, RLL, LLL and lingula with air 
bronchograms. Air trapping. 
Not done Milky Numerous macrophages, scattered 
lymphocytes and neutrophils. 
70% lipid laden macrophages with abundant 
extracellular lipid. No free lying PAS 
material. Surfactant A and B present on 
immunohistochemistry. Possible lipid like 
material present on electron microscopy. 
02 Diffuse ground glass opacification 
confluent in the RUL. Bilateral patchy 
consolidation in all lobes 
predominantly on the right with 
peripheral sparing. 
Not done Cloudy  Numerous macrophages, scattered 
lymphocytes and neutrophils. 
>50% lipid laden macrophages with 
abundant extracellular lipid. Negative PAS. 
03 Diffuse airspace opacification, 
parahilar and non-segmental RUL, 
LUL, RML and lingula. 
Homogenous ground glass 
opacification. Airspace 
consolidation in a perihilar 
distribution. Interlobular septal 
Cloudy  Numerous macrophages, scattered 
lymphocytes and neutrophils. Abundant lipid 
laden macrophages and extracellular lipid. 
 
 
thickening with characteristic 
crazy paving pattern. 
[Cell count: neutrophils 66%, lymphocytes 
16%, monocytes 14%, eosinophils 4%] 
04 Diffuse airspace opacification 
predominantly of the right lung. 
Ground glass opacification. 
Confluent consolidation 
involving RUL with sparing of 
the posterobasal and anterior 
segment of the RLL. 
Characteristic crazy paving 
pattern secondary to interlobular 
septal thickening in both lower 
lobes. 
Cloudy  Numerous macrophages, scattered 
lymphocytes and neutrophils. Abundant lipid 
laden macrophages and extracellular lipid. 
PAS negative. Normal lamella bodies and 
focal lipid droplets on electron microscopy. 
Squamous metaplasia suggestive of viral 
infection. 
[Cell count: neutrophils 31%, lymphocytes 
18%, monocytes 48%, eosinophils 1%, 
mesothelial cells 2%] 
05 Diffuse ground glass opacification 
more confluent in the RUL, RML, left 
parahilar segmental LUL and lingula, 
and patchy in the lower lobes 
bilaterally. 
Diffuse ground glass 
opacification and airspace 
consolidation of both lower 
lobes particularly RLL. 
Interlobular septal thickening 
and crazy paving. Increased 
perihilar and mediastinal soft 
Milky  Numerous macrophages, scattered 
lymphocytes and neutrophils with abundant 
lipid laden macrophages and extracellular 
lipid. PAS negative. 
 
 
tissue suggestive of 
lymphadenopathy. 
06 Diffuse ground glass opacification 
with a right sided predominance and 
confluent in the right upper lobe. 
Diffuse ground glass 
opacification with a lower zone 









biopsies taken of the 
RML and RLL. 
Numerous macrophages, scattered 
lymphocytes and neutrophils. 50% lipid 
laden macrophages with abundant 
extracellular lipid. Negative PAS. 
 
Abundant lipid laden macrophages and 
extracellular lipid. Negative PAS. Absent iron 
laden macrophages. Mild lymphocytic 
interstitial inflammation. No fibrosis. Normal 
lamellar bodies and lipid droplets present on 
electron microscopy. 
 
07 Diffuse homogenous ground glass 
opacification in both right and left 
lung fields with dense airspace 
opacification. 
Predominant central, basal and 
posterior involvement, distinct 
sparing of the peripheral lung 
zones with geographical pattern 
Purulent (“thick 
yellow”) BAL fluid 
Numerous vacuolated macrophages and 
neutrophils, scattered lymphocytes. 
Abundant lipid laden macrophages and 
extracellular lipid. PAS negative. Scattered 
bacterial cocci.  
 
 
involvement (interlobular septal 
thickening and crazy paving). 
 
[Cell count: neutrophils 88%, lymphocytes 
3%, monocytes 9%] 
08 Diffuse homogenous ground glass 
opacification predominantly on the 
right, slightly sparing part of the left 
lower lobe. Bilateral air 
bronchograms. 
Dense consolidation with air 
bronchograms in the posterior 
segments of the upper and 
lower lobes bilaterally with some 
sparing of the anterior segments 
both basally and upper lobes. 
Areas of ground glass 
opacification in non-
consolidated areas of the lung. 
Focal areas measuring fat 
density (-7 to 20HU) within the 
consolidated lung. Minimal 
interlobular septal thickening. 
Milky BAL. Moderate macrophages and neutrophils, 
scattered lymphocytes. Abundant lipid laden 
macrophages and extracellular lipid. PAS 
negative. Scattered fungal spores and 
pseudohyphae compatible with candida. 
 
[Cell count: neutrophils 50%, lymphocytes 
36%, monocytes 14%] 
09 Confluent airspace opacification of 
the RUL, RML and LLL. 
Mass like opacification within 
the posterior segment of the 
RUL that demonstrates mild 
Milky BAL  Abundant macrophages, scattered 




Homogenous ground glass 
opacification predominantly in 
the posterior segments. Mild 
smooth interlobular septal 
thickening. 
lipid laden macrophages and extracellular 
lipid. Numerous acid-fast bacilli. Candida. 
 
[Cell count: neutrophils 12%, lymphocytes 
31%, monocytes 57%] 
10 Diffuse ground glass opacification, 
predominantly of the right lung - 
confluent and dense. Patchy lingula 
airspace opacification. 
Diffuse bilateral ground glass 
opacification with lower zone 
predominance. More 
pronounced on the right, with 
confluent right posterior 
subpleural airspace 
consolidation. Interlobular septal 
thickening and crazy paving 
pattern. 
Milky BAL  Abundant macrophages, admixed 
lymphocytes and neutrophils. Abundant 
foamy lipid laden macrophages and diffuse 
extracellular lipid. Mixed commensal 
bacteria. 
 
[Cell count: neutrophils 33%, lymphocytes 
17%, monocytes 50%, eosinophils 0%] 
11 Lobulated density occupies entire 
right hemithorax sparing the right 
costophrenic angle, a confluent 
expansile consolidation. Patchy 
Bilateral pneumonia (airspace 
opacification) with significant 
expansile component of the 
right. Multiple nodules. RML 
Cloudy and clear 
BALs 
Abundant lipid laden macrophages >50%. 
Candida and numerous acid-fast bacilli. 20% 
lipid laden macrophages and extracellular 
lipid present in second sample. 
 
 
airspace opacification of the LUL and 
lingula. Hyperinflated lungs. 
atelectasis. No air trapping. 
Small sub-centimeter enhancing 
paratracheal, precarinal, 
subcarinal and bilateral axillary 
lymphadenopathy. 
 
[Cell count: neutrophils 24%, lymphocytes 
8%, monocytes 70%, eosinophils 0%] 
12 Diffuse ground glass opacification 
bilaterally predominantly RUL and 
RML. 
None Milky BAL  Abundant foamy macrophages and scattered 
lymphocytes. Absent neutrophils and 
eosinophils. Diffuse lipid laden macrophages 
and abundant extracellular lipid. PAS 
negative. Mixed commensal bacteria. 
 
[Cell count: neutrophils 33%, lymphocytes 
17%, monocytes 50%, eosinophils 0%] 
 544 





E-text: Additional information on qualitative methodology and results 548 
 549 
Research team and reflexivity 550 
The lead researcher, a Kenyan paediatrician with formal training and experience 551 
in qualitative research, currently training as a pulmonology fellow, may or may not 552 
have established a relationship with participants prior to commencement of the 553 
qualitative phase of the case series. The research team also comprised senior 554 
researchers with extensive experience in the fields of paediatric pulmonology, 555 
radiology and pathology. 556 
 557 
Data collection process 558 
Caregivers listed were called using phone numbers provided in their hospital records 559 
and invited to the qualitative phase of the study that was conducted telephonically or 560 
in person based on patient preference. Verbal or written informed consent was 561 
obtained from caregivers who agreed to participate in the study. Caregivers whose 562 
phone numbers were unreachable were tracked in the community by a social worker 563 
using their contact address and details provided in hospital records. Caregivers who 564 
declined telephonic invitation, or did not provide verbal informed consent, were 565 
excluded from the qualitative phase of the study and we only included their 566 
documented retrospective data. Employing qualitative interviewing skills using open 567 
ended questions outlined in the interview guide, D.M. obtained recall data of practices 568 
including oil use if any, type(s), age(s) at onset of use, route of administration, 569 
frequency, duration, reasons for oil use, underlying illnesses/concerns, and the current 570 




In this study we sought to gain an in-depth understanding of oil administration 573 
practices from the perspective of individual caregiver level and thus our choice of 574 
individual interviews. Methodologically, this approach is powered for information as 575 
the topic is of a narrow scope, it is backed by an established theoretical background, 576 
the participants held characteristics that are highly specific for the study aim, we 577 
designed our interview guide to enable a focused interview dialogue, and our chosen 578 
analytic strategy was heading for an in-depth analysis of narratives (10). All possible 579 
caregivers of children with an ascertained outcome who could be reached and 580 
provided informed telephonic consent were interviewed and provided sufficient 581 
variations. An empathetic approach was employed during the conduct of all interviews 582 
being cognisant of not attributing any blame to the caregivers of study participants. A 583 
log of socio-demographic characteristics of non- participants was kept to determine 584 
how they differed from participants. Data obtained from participants in the qualitative 585 
phase of the study were audio recorded and the researcher concurrently took notes. All 586 
interviews were conducted in a private room, without taking names of the caregivers 587 
to maintain privacy and confidentiality. For non-English speaking/non-English fluent 588 
caregivers, the services of a trained interpreter were enlisted to ensure potential 589 
participants understood the interview. 590 
 591 
Analyses 592 
Qualitative data around oil practices associated with ELP in children were manually 593 
coded solely by D.M. following transcription of the audio-recorded interviews. These 594 
data were reduced and analyzed into summaries that were reconstructed and 595 




I: Interview Guide 598 
Date of Interview                                                                 Participant Enrollment ID  
                                         
          dd                   mmm                            yyyy                                                        
Section 1: How is your child doing today?  
[Only use as probes, allow for detailed caregiver description] 
 Cough?                                    □ No    □ Yes …. Duration ________ (days)     
Hotness of body?                     □ No    □ Yes …. Duration ________ (days)     
Fast breathing?                        □ No    □ Yes …. Duration ________ (days)     
Other (specify)   ___________________________________________________      
Section 2: Tell me, have you ever used any oil for your child?  
[Only use as probes, allow for detailed caregiver description] 
 □ No    □ Yes    (specify)  ________________         
Type(s) of oil? □ No □ Yes (tick all that apply)  
Mineral   □ No  □ Yes  (specify) _____________ 
                                                                              
Vegetable □ No  □ Yes  (specify) _____________ 
                                                                               
Animal     □ No  □ Yes (specify) ______________ 
Age at onset of use? Years Months 
Route of administration?  □ Nose    □ Mouth  □ Topical    □ Other 
______________________________________________________   
Amount? Milliliters (Ml)   and Frequency? Hourly   
Total Amount Daily? Ml        
 
 
Duration?  Days     Months     Years 
WHY? Reasons for oil use/Past illnesses/concerns at the time of oil use: 
□ Constipation (specify) ___________ □ Colic (specify) 
___________________  
□ Nasal stuffiness (specify) ______________   □ Religion (specify) _________     
□ Culture (specify) _______________    □ Other (specify)______________   
Section 3: Does your child have any problems swallowing? Does your child 
have any other condition/problems?  
[Only use as probes, allow for detailed caregiver description] 
 
 
Co-morbidities:   
Any underlying swallowing problem? □ No  □ Yes (specify)____________ 
□ Other (specify) _____________________________________________    
 
Section 4: Tell me, are you using any oil for your child at the moment?  
[Only use as probes, allow for detailed caregiver description]  
 
 
□ Yes (why)____________    □ No     
When did you stop?                                             
                                                               dd                   mmm                            yyyy      
Why did you stop?  
□ The doctor told me   □ It was making my child sick    
□ Other (specify) _____________________________________ 
Section 5: Do you have other children? How old are they now? Did they have 
any respiratory problems (at what age, what problem, any hospital 
admissions)? Did you ever give them oil (age of onset, route, type, amount, 
 
 
frequency, duration, reason)? [Only use as probes, allow for detailed caregiver 
description] 
 
□ No    □ Yes (How many?)      
How old? Any respiratory problems? Did you give them oil? 
1.   □ No  □ Yes (specify) ________  ; □ No  □ Yes (specify) 
_______ 
2.   □ No  □ Yes (specify) ________  ; □ No  □ Yes (specify) 
________ 
3.   □ No  □ Yes (specify) ________  ; □ No  □ Yes (specify) 
________ 
4.   □ No  □ Yes (specify) ________  ; □ No  □ Yes (specify) 
________ 
5.   □ No  □ Yes (specify) ________  ; □ No  □ Yes (specify) 
________ 
Section 6: Do you know other people who use oils? Who? How? Why? 
[Only use as probes, allow for detailed caregiver description] 
 □ Family members (specify e.g. mother, sister, aunty, cousin, niece etc.) 
_____________________________________________________________  
□ Community members (specify e.g. friends, neighbors, religious circles, 
general etc.) 
________________________________________________________ 






II: Emergent themes and selected quotes 600 
A. Oil administration is a nearly universal cultural practice 
 
ID-11: “Almost every single Zimbabwean (uses oil). Every Zimbabwean, because that is what they 
say. Even when he was coughing and I decided to bring him to hospital and they were like, ‘No, just 
keep giving him the oil’ for the wind. In Cape Town, Johannesburg, everywhere (Zimbabweans 
everywhere use oil). Noo… (I wouldn’t say it is religious). I don’t know (why one child will get a 
teaspoon and another a tablespoon). (They told me) Teaspoon, yes. Once a day. Sometimes three 
times but I preferred once a day. Because I thought he would get a lot of fat. People just use any oil, 
but I decided to use olive oil. I don’t know, because it is natural I think.” 
 
ID-12: “All the Zimbabweans use oil. If you don’t use mti, you will use oil. (Mti) that cultural herbs. 
Yea, so if you don’t use that cultural herbs then you use cooking oil. You must use only one because 
if you use herbs then it is fine. The only problem when you use herbs, if you meet, another baby with 
herbs they fight. Those herbs fight each other. That is why we don’t want to use herbs because if 
yours get weak then he gonna pass or something is gonna happen. (They get mti) even from 
sangoma or like our grandfather and grandmother or they know where to get those mti because it is 
just roots or leaves of the trees. (I chose to give oil) because where I am going to church they don’t 
use mti. Yes but sometimes you can buy…, like here there is colic oil, there is different, lots of…, but 
me I just try one from ‘Pharmacy X’ then I stop it because when I use that one the baby doesn’t sleep. 
It is not a type of oil, it is like water. In Zimbabwe it is like culture that if you don’t use mti, you use oil 
but most of the people are using oil. They (People from Zimbabwe) are also religious but some of 
them are scared to use mti. Like me I am also scared to use mti. You gonnna get the wrong one then 
baby gonna pass away. You don’t know this is the right one or this is the… When I get out of the 
hospital (after delivery). Yes (I started giving oil). The oil is like for the wind and for the head for the…. 
‘Nava’ (anterior fontanelle). They said if you give cooking oil like my baby’s.. it was too big.. so they 
said you must give cooking oil and it is gonna come back to normal and for the wind. Even if you give 




ID-10: “Yea, it is true we used to do that because our elders they teach me, they teach us already so 
I believe in them because they did years ago, you see. So now we are calling it our tradition for 
everyone. Yea, they use oil. Even now they are going to force me at home; you can use it. If I am 
complaining to them my child is struggling to push ‘kaka’ (stool) they say, ‘You must give the child 
oil.’. But from now, no I cannot. It is not a force, but if I complain to them, they are going to say, ‘How 
is the boy? I am going to tell them, ‘He is struggling to do this and do this.’ Already they will say, ‘You 
must give the boy oil’. I cannot do that again. You know I love my boy. I am going to lie to them I am 
giving him to shut them out, that is all. 
 
ID-03: “Yes (I have ever used oil). Olive oil. We started at six months. One teaspoon for each day for 
two weeks. Then I stopped. Because in our culture every newborn child we used to give cooking oil 
to clean the stomach… when the baby has a problem with the stomach we would give oil to help…. 
She was suffering from constipation, yea. If she wants to make a pupu, she can make a hard pupu, 
so suffering to have a pupu, so they say we can help like that. We just gave it for two weeks then I 
stopped. (I stopped because) She was okay. So everyone in my culture they give children oil. they 
just…, I don’t know how they give it but maybe a teaspoon maybe two times a day, I don’t know but 
they give oil. If you get a child you have to give the child oil. It will help in cleaning the stomach. We 
just boil it and then make it warm and then you give the child. Other people they would just add a 
little bit of salt, others just give plain like that.”  
 
B. One caregiver reports no history of oil administration 
 
ID-04: “No, for us no, we don’t use oil at all… I do see some of them (other Zimbabweans) but I don’t 
know what it is for. I saw them in Red Cross but I don’t know, if you are mixed up more than from 
your country. So I don’t know when, the age and in which form, I don’t know.” 
 




ID-05: Yes (I have ever used oil). Cooking oil. The one we use to cook. (I started) the day I gave 
birth. The following day when I was at home after I was discharged from hospital when I went home 
I started to give him. I put the oil in a pot dish then I put little salt then I boil.  I put it on the stove then 
it boils, then I put somewhere it gets cold then I sometimes give him three teaspoons or two 
teaspoons, the small one. Sometimes I give him two times, sometimes once. (I gave him oil) because 
of the stomach. Sometimes he feels painful, he cannot even pupu so if I give oil it was like it was 
helping him for his stomach. (I stopped) long time now. Like three to six months. I cannot remember. 
(I stopped) because he refused to drink it. Sometimes he holds the spoon and throws it away. And 
also at that time, he was not struggling to pupu or so,so I check the pupu was fine and there was no 
struggling so I decided to stop giving him.  
 
ID-12: “Yes (I have ever used oil for my child)… for the baby you give teaspoon in the morning and 
one teaspoon in the evening… Sometimes he coughs because he doesn’t want it, but we don’t have 
choice because even when I go to Zimbabwe they say you must force him to drink you cannot say 
the baby doesn’t want because he is still young.” 
 
D. Some siblings given oil developed overt respiratory problems and 
complications 
 
ID-08 [Interpreted]: Yes (I have used oil for my child). Cooking oil. Sun flower oil. (I started using it 
when he was) two months. (I would give) morning teaspoon, afternoon teaspoon, evening teaspoon. 
(I used it for) three months. (I would give it to) his mouth. When the child was born, the anterior 
fontanelle was pulsating a lot. So I asked my mum for advice and she said if I don’t want the fontanelle 
to pulsate, I give him oil. (I would give it for) one year (so that the anterior fontanelle does not pulsate). 
At home in Zimbabwe there is some black substance we they put on the anterior fontanelle which 
can be given to stop the pulsating… No (I do not have other children), I had one child who passed 
away… When I left ‘YYY’ which is in Zimbabwe, he was coughing. The child was coughing and when 
I came with the child here (Cape Town, South Africa) the coughing continued and it was actually 
worse. Then I went to the clinic with the child, and the child passed away that same day. (He was) 
 
 
two months (when he started coughing). Yes (I know other people who use oil). (My) older brother’s 
wife used oil and the child’s anterior fontanelle never pulsated afterwards… There are people that I 
stay with who also use oil. (They are from) Zimbabwe as well. No, I have not seen people from this 
country using it… Yes, I used oil for my first baby. (I would give) a teaspoon in the morning, teaspoon 
in the afternoon, teaspoon in the evening… 
 
E. Some siblings given oil did not develop overt respiratory problems 
 
ID-05: Yes (I have other children). The other one is six years. A boy. Yes, I gave oil also. Yes, but 
that one my mother was staying with him until he was one year six months then he came to me. I 
don’t know how many teaspoons. It is my mother who was giving him. The six years old didn’t have 
any problem, I don’t want to lie. That one was fine. Even me as I was growing up they (my sisters) 
gave me oil. I was also drinking oil. Yes. If my stomach is painful, my mother wanted to boil oil but I 
refused because you know oil is not sweet to drink. And sometimes if I feel stomach pain I always 
put it with salt and then I try to go to the toilet and my stomach is clean. But now I just think about oil 




F. Oil is also given to adults 
ID-12: “Yes (I have ever used oil for my child), even for me. I was using it when I was pregnant 
because it is our culture. So when I was pregnant I was also drinking oil from three months but when 
I gave birth…, I noticed it today, that when I gave birth I was also admitted at Facility X (the secondary 
level health facility that referred her child to our unit) with a lung problem. Yea, I was in High Care, 
that thing came in today when I was in theatre (waiting for her son undergoing the bronchoscopy). I 
didn’t think about it. I was drinking just once. One tablespoon. Once a day. That cooking oil.”” You 
cook it but when you drink it you must make it warm then you drink… because they say…, our elders 
say if you drink cooking oil it is gonnna make a way for the baby to come out. Me I was drinking one 
 
 
tablespoon but for the baby you give teaspoon in the morning and one teaspoon in the evening… 
Sometimes he coughs because he doesn’t want it, but we don’t have choice because even when I 
go to Zimbabwe they say you must force him to drink you cannot say the baby doesn’t want because 
he is still young. You cook it but when you drink it you must make it warm then you drink… because 
they say…, our elders say if you drink cooking oil it is gonnna make a way for the baby to come out. 
Me I was drinking one tablespoon but for the baby you give teaspoon in the morning and one 
teaspoon in the evening… Sometimes he coughs because he doesn’t want it, but we don’t have 
choice because even when I go to Zimbabwe they say you must force him to drink you cannot say 




G. Oil is also administered to children of local South African descent 
ID-10: “Yea (there are others not from Zimbabwe who use oil). I was in hospital…, the time I was in 
(Hospital Y, a secondary referral hospital in the province), there was a coloured woman next to me. 
Her boy was like my boy, pneumonia, fever, what what. So, she said to me, ‘Even me I used to give 
my boy cooking oil, but I used to give him in the [then points to the ears], yes and in the nose.’ She 
said, ‘If my boy is coughing too much, I used to give him in the mouth to make his chest soft.’ She 
said so to me. Even the sisters, mhh, what can I say, Venda sisters at [Hospital Y] they say so. They 
say, ‘In our cultures…’ they say, ‘We used to do that.’ I think Vendas…, other Vendas, they are in 
Zimbabwe. Some of them, they say, ‘We used to do this to our children’. (They would give the oil 
through the) nose, mouth, the ears. Yea, for the same reason (to help with the stool), because I 
asked them… (they use) sunflower oil. Yes, they say so to me. Another woman who was next, after 
that one…. she showed me a sweet oil and she told me, ‘You must buy a sweet oil in the pharmacy. 
Yea, sweet oil not sunflower’. No (she was not from Zimbabwe), coloured again. She said, ‘You guys 
you must stop using sunflower. Let me show you my sweet oil that I was using to give my boy’. She 








Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist 606 
Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 607 
(COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health 608 
Care. 2007. Volume 19, Number 6: pp. 349 – 357 609 
No.  Item  
 
Guide questions/description Reported on Page 
# 
Domain 1: Research team 
and reflexivity  
  
Personal Characteristics    
1. Interviewer/facilitator Which author/s conducted the interview or 
focus group?  
E-text 
2. Credentials What were the researcher’s credentials? E.g. 
PhD, MD  
E-text 
3. Occupation What was their occupation at the time of the 
study?  
E-text 
4. Gender Was the researcher male or female?  N/A 
5. Experience and training What experience or training did the researcher 
have?  
E-text 
Relationship with participants    
6. Relationship established Was a relationship established prior to study 
commencement?  
E-text 
7. Participant knowledge of the 
interviewer  
What did the participants know about the 
researcher? e.g. personal goals, reasons for 
doing the research  
E-text 
8. Interviewer characteristics What characteristics were reported about the 
interviewer/facilitator? e.g. Bias, assumptions, 
reasons and interests in the research topic  
E-text 
Domain 2: study design    
Theoretical framework    
9. Methodological orientation What methodological orientation was stated to E-text 
 
 
and Theory  underpin the study? e.g. grounded theory, 
discourse analysis, ethnography, 
phenomenology, content analysis  
Participant selection    
10. Sampling How were participants selected? e.g. 
purposive, convenience, consecutive, snowball  
E-text 
11. Method of approach How were participants approached? e.g. face-
to-face, telephone, mail, email  
E-text 
12. Sample size How many participants were in the study?  Results and E-text 
13. Non-participation How many people refused to participate or 
dropped out? Reasons?  
Results and E-text 
Setting   
14. Setting of data collection Where was the data collected? e.g. home, 
clinic, workplace  
E-text 
15. Presence of non-
participants 
Was anyone else present besides the 
participants and researchers?  
E-text 
16. Description of sample What are the important characteristics of the 
sample? e.g. demographic data, date  
Results and E-text 
Data collection    
17. Interview guide Were questions, prompts, guides provided by 
the authors? Was it pilot tested?  
E-text 
18. Repeat interviews Were repeat inter views carried out? If yes, how 
many?  
N/A 
19. Audio/visual recording Did the research use audio or visual recording 
to collect the data?  
E-text 
20. Field notes Were field notes made during and/or after the 
interview or focus group? 
E-text 
21. Duration What was the duration of the interviews or 




22. Data saturation Was data saturation discussed?  E-text 
23. Transcripts returned Were transcripts returned to participants for 
comment and/or correction?  
N/A 
Domain 3: analysis and 
findings  
  
Data analysis    
24. Number of data coders How many data coders coded the data?  E-text 
25. Description of the coding 
tree 
Did authors provide a description of the coding 
tree?  
N/A 
26. Derivation of themes Were themes identified in advance or derived 
from the data?  
E-text 
27. Software What software, if applicable, was used to 
manage the data?  
E-text 
28. Participant checking Did participants provide feedback on the 
findings?  
N/A 
Reporting    
29. Quotations presented Were participant quotations presented to 
illustrate the themes/findings? Was each 
quotation identified? e.g. participant number  
Results and E-text 
30. Data and findings 
consistent 
Was there consistency between the data 
presented and the findings?  
Results and E-text 
31. Clarity of major themes Were major themes clearly presented in the 
findings?  
Results and E-text 
32. Clarity of minor themes Is there a description of diverse cases or 
discussion of minor themes?       







Appendix 1: Data Capture Instruments 
 
 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Date of Interview                                                                            Participant Enrollment ID  
                                            
           dd                   mmm                            yyyy                                                        
Section 1: How is your child doing today?  
[Only use as probes, allow for detailed caregiver description] 
 
Cough?                                    □ No    □ Yes …. Duration ________ (days)     
Hotness of body?                     □ No    □ Yes …. Duration ________ (days)     
Fast breathing?                        □ No    □ Yes …. Duration ________ (days)     
 
Other (specify)   ________________________________________________________       
               
Section 2: Tell me, have you ever used any oil for your child?  
[Only use as probes, allow for detailed caregiver description] 
 
□ No    □ Yes    (specify)  ________________         
 
Type(s) of oil? □ No □ Yes (tick all that apply) Mineral   □ No  □ Yes  (specify) _____________ 
                                                                             Vegetable □ No  □ Yes  (specify) _____________ 
                                                                              Animal     □ No  □ Yes (specify) ______________ 
 
Age at onset of use? Years Months 
 
Route of administration?  □ Nose    □ Mouth  □ Topical    □ other ___________   
 
Amount? Milliliters (Ml)   and Frequency? Hourly   
 
Total Amount Daily? Ml        
 
Duration?  Days     Months     Years 
 
WHY? Reasons for oil use/Past illnesses/concerns at the time of oil use: 
□ Constipation (specify) _________ □ Colic (specify) _______ □ Nasal stuffiness (specify) _____   
□ Religion (specify) _________    □ Culture (specify) _________    □ Other (specify)___________   
Section 3: Does your child have any problems swallowing? Does your child have any other 
condition/problems?  
[Only use as probes, allow for detailed caregiver description] 
 
 Co-morbidities:  Any underlying swallowing problem? □ No  □ Yes (specify) _________ 
           □ Other (specify) _______________________________    
 
Section 4: Tell me, are you using any oil for your child at the moment?  
[Only use as probes, allow for detailed caregiver description]  
 
 □ Yes (why)____________    □ No     
 
When did you stop?                                             
                                                               dd                   mmm                            yyyy      
 
Why did you stop?  
□ The doctor told me  □ It was making my child sick  □ Other (specify) ______ 
 
Section 5: Do you have other children? How old are they now?  
Did they have any respiratory problems (at what age, what problem, any hospital admissions)?  
Did you ever give them oil (age of onset, route, type, amount, frequency, duration, reason)? 
[Only use as probes, allow for detailed caregiver description] 
 
□ No    □ Yes (How many?)      
 
How old? Any respiratory problems? Did you give them oil? 
1.   □ No  □ Yes (specify) ______________  ; □ No  □ Yes (specify) ______________ 
2.   □ No  □ Yes (specify) ______________  ; □ No  □ Yes (specify) ______________ 
3.   □ No  □ Yes (specify) ______________  ; □ No  □ Yes (specify) ______________ 
4.   □ No  □ Yes (specify) ______________  ; □ No  □ Yes (specify) ______________ 
5.   □ No  □ Yes (specify) ______________  ; □ No  □ Yes (specify) ______________ 
Section 6: Do you know other people who use oils? Who? How? Why? 
[Only use as probes, allow for detailed caregiver description] 
 
□ Family members (specify e.g. mother, sister, aunty, cousin, niece etc.) ______________   
□ Community members (specify e.g. friends, neighbors, religious circles, general etc.) _____________ 























































Telephone Invitation Protocol 
 
Good Morning/Afternoon _________________, 
My name is Dr. Diana Marangu. I am part of a team that is conducting a study at Red Cross Children’s Hospital 
to understand a lung condition in children associated with swallowed oil called lipoid pneumonia. We would like 
to invite you to participate in this study because your child may have had this condition. Your participation is 
completely voluntary. If you agree to give consent to participate in this study, we will ask you some questions on 
the telephone. This will take approximately 15-20 minutes of your time. All this information is private and 
confidential and we will only use it for the purposes of this study. 
 Do you have any questions?  What are your thoughts? [give time for response – note response]  
  Willing to participate in the study – Proceed to Verbal Consent 
  Not willing to participate in the study at the moment, but will require further information or 
      more time to make a decision 
  Information required: _________________________ 
  Timelines to be contacted: _________________________ 
  Telephone number willing to be contacted on: _________________________ 
  Not willing to participate in the study, child deceased 
  Not willing to participate in the study 
 
Thank you very much for your time.  Please do not hesitate to contact me in the future if you have 















Appendix 2B: Verbal Consent 
Clinical, radiological and pathological characteristics and treatment outcomes of children with 
exogenous lipoid pneumonia: a case series from South Africa 
Introduction: You are being asked to participate in this research study by Dr. Diana Marangu from the University 
of Cape Town and Red Cross Children’s Hospital as part of her Masters in Philosophy degree training in 
Paediatric Pulmonology.  
Purpose of the study: This study aims to understand a lung condition in children associated with giving babies 
or children oil called lipoid pneumonia. Your child was selected as a possible participant in this study because 
s/he may have had this condition. 
Procedures: If you agree to give consent for your child to participate in this study, we will ask you some questions 
that will take approximately 15-20 minutes of your time. We will audio record this conversation so that we do not 
miss out on important details that you tell us.  
Risks of participation: The risks from your participation are minimal. You may find some of the questions and 
responses to be tiresome. Disclosure (accidental or otherwise) of personal information is very unlikely but may 
occur. To reduce this risk, all research staff will be sworn to confidentiality. 
Anticipated Benefits: Benefits of your child’s participation are aimed at understanding practices related to this 
condition to prevent avoidable illness and recognize and treat this condition in other children early. 
Confidentiality: We will respect your privacy. Data will be stored in a secure web-based database. Results 
published or presented in public will not have information that would allow people to identify you. 
Voluntariness: Participation in this study is out of your own free will. You may choose not to participate with no 
consequences whatsoever. 
Who do I contact if I have questions or problems? For any enquiries or further clarification about the study, or 
should you experience any harm by participating in this study, contact the Principal Investigator Dr. Diana 
Marangu: +27-733- 396219. For questions about your rights as a research participant, you should contact 
Professor Marc Blockman, the Chair of the Human Ethics Research Committee, Office situated at the Old Main 
Building of Groote Schuur Hospital, Floor E53, Room 46, Observatory, 7925. 
Do you have any questions?  What are your thoughts?   
  Willing to participate in the study                                Not willing to participate in the study 
 
Investigator initials: _____________________________       Date: ___________________ 
Thank you very much for your time.  Please do not hesitate to contact me in the future if you have 
any (other) questions or require further clarification. Have a good day/morning/afternoon. 
 
 
“CLINICAL-RADIOLOGICAL-PATHOLOGICAL CHARACTERISTICS OF CHILDREN WITH 
EXOGENOUS LIPOID PNEUMONIA: A CASE SERIES AND SYSTEMATIC REVIEW” STUDY 
 
CONFIDENTIALITY AGREEMENT – PRINCIPAL INVESTIGATOR/RESEARCHERS 
 
Confidentiality 
Researchers shall treat all contact information i.e. telephone numbers and contact addresses of 
study participants, learned from the Red Cross Children’s Hospital medical folders and contact 
information software ‘Clinicom’ during the study, as confidential. Researchers shall not use this 




Researchers shall withdraw immediately from encounters that they perceive to be in violation of 
this Confidentiality Agreement. In the event of a breach by the researchers of this Confidentiality 
Agreement, Red Cross Children’s Hospital in any dispute shall be entitled to seek the remedies 
of injunction, specific performance or other equitable relief, for any threatened or actual breach of 
this Confidentiality Agreement by the researcher. Further, Red Cross Children’s Hospital shall be 
entitled to recover from the researcher costs incurred in such dispute including without limitation 
its reasonable legal fees.  
 
By signing this document, I am verifying that I have read, understand and agree to all the 
provisions listed in the above Confidentiality Agreement. 
  
Name (printed): DR. DIANA MWENDWA MARANGU 
                                      Researcher 
E‐mail address: dmarangu@uonbi.ac.ke 











Appendix 3: Technical Appendix 
 
 
Systematic review protocol 
 
Systematic review - Table 1 
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Clinical-radiological-pathological characteristics and treatment outcomes of 
children with suspected exogenous lipoid pneumonia: a systematic review. 
 
Date: 30th May 2017 
 
Authors & Affiliations:  







1University of Nairobi, Kenya 
2University of Cape Town, South Africa 
 
Review question(s):  
1. What are the clinical-radiologic-pathological characteristics of children with suspected 
exogenous lipoid pneumonia?  
2. What are the treatment outcomes of children with suspected exogenous lipoid 
pneumonia?  
3. What is the efficacy of treatment modalities (therapeutic lavage, steroids, 
discontinuation of oil) for suspected exogenous lipoid pneumonia in children? 
 
Searches: 
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We will consider studies in indexed and peer reviewed sources, and employ a multi-
concept boolean search strategy based on the Population, Intervention, Control, 
Outcome, Timing and Setting (PICOTS) framework(1). (Appendix 1) This search strategy 
will use keywords related to exogenous lipoid pneumonia in children and will be restricted 
to English publications published within the last 50 years. This period was arbitrarily 
deemed to represent data that will be currently relevant.The electronic databases that we 
will use for searching will include Pubmed, EMBASE, Web of Science, SCOPUS, CINAHL 
and the Cochrane Library. For example, we will use the following search strategy in 
Pubmed: ("child"[MeSH Terms] OR Child[tw]) OR ("infant"[MeSH Terms] OR infant[tw]) 
AND ("pneumonia, lipid"[MeSH Terms] OR ("pneumonia"[All Fields] AND "lipid"[All 
Fields]) OR "lipid pneumonia"[All Fields] OR ("exogenous"[All Fields] AND "lipoid"[All 
Fields] AND "pneumonia"[All Fields]) OR "exogenous lipoid pneumonia"[All Fields]) AND 
(1967:2017[dp]) AND "English"[la]  (Appendix 2).  
 
Types of studies to be included: 
Inclusion: Studies in which children <18 years old are suspected to have exogenous lipoid 
pneumonia. Exogenous lipoid pneumonia will be suspected under the following 
conditions:1) History of oil administration related to time of presentation/diagnosis, 2) 
Clinical presentation of persistent or recurrent unexplained pneumonia associated with 
hypoxia or tachypnea, 3) Radiological evidence of persistent diffuse alveolar infiltrates on 
chest radiograph or computed tomography (CT) chest, and/or 4) Histological findings on 
bronchoalveolar lavage (BAL) or lung biopsy that are consistent with exogenous lipid 
content. Two levels of case definitions will be applied in this systematic review: a) 
Suspected exogenous lipoid pneumonia, for cases in which a histological diagnosis is not 
available/documented; and b) Confirmed exogenous lipoid pneumonia, for cases that 
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include histological findings. Eligible study designs include retrospective or prospective: 
(a) analytic studies (cross sectional, case-control, cohort or intervention studies), (b) 
descriptive studies (case reports, case series, cross sectional studies), and (c) qualitative 
studies. We will include studies that include adults along with children if the data for adults 
can be separated and excluded.  
 
Exclusion: Letters, editorials, commentaries, all types of reviews, meta-analyses and non-
human studies will be excluded. 
 
Condition or domain being studied: 
Suspected exogenous lipoid pneumonia in children. 
 
Participants/population: 
Studies done in children (age <18 years) globally. 
 
Intervention(s), exposure(s): 
For interventional studies, the intervention may be a treatment modality e.g. therapeutic 
lavage, steroid use, discontinuation of oil.  
 
Comparator(s)/ controls: 
For interventional studies, the control will be the group without the intervention e.g. no 
therapeutic lavage. For case control studies, controls are children without exposure to the 
risk factors e.g. no history of exposure to oil. For cohort studies, the comparator will be the 
group unexposed to risk factors. For case series and case reports, there will be no control 
group. 
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Context: 




1. Clinical-radiologic-pathological characteristics of children with suspected exogenous 
lipoid pneumonia, specifically caregiver reason/s for oil usage and the predominant 
pattern of clinical and radiological presentation. 
2. Treatment outcomes of children with suspected exogenous lipoid pneumonia, 
specifically proportion of children with clinical resolution, proportion of children with 
radiological resolution, median time to clinical resolution, median time to radiological 
resolution, and proportion of children who do not survive (mortality). 
3. Efficacy of treatment modalities (therapeutic lavage, steroids, other) for suspected 
exogenous lipoid pneumonia in children, specifically odds ratio/risk ratio. 
 
Secondary outcome(s) 
1. Factors associated with exogenous lipoid pneumonia in children. 
 
Data extraction, selection and coding: 
Studies will be reviewed based on the inclusion and exclusion criteria by as follows: 
 
Stage 1: The primary reviewer (D.M) will screen titles of all citations that meet study 
eligibility in the initial screen. Studies which are approved by this author will move to the 
second stage of appraisal.  
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Stage 2: Abstracts of studies selected in stage one will be obtained and evaluated for 
eligibility into the systematic review by the primary reviewer. 
 
Stage 3: In the third screen, full texts of any studies selected in the second screen will be 
reviewed to determine eligibility into the final analysis. To account for any differences in 
inferences made, the primary reviewer will keep a log of all studies excluded and reasons 
for exclusion after the 1st, 2nd and 3rd screen.  
 
A standardized pre-tested data extraction form will be used. (Appendix 3) Senior reviewers 
will be consulted during this process whenever required. Broad characteristics under 
which data will be extracted will include: clinical-radiological characteristics and treatment 
outcomes in children with suspected exogenous lipoid pneumonia. Specific information 
that the primary reviewer will record from each study will include: citation details (first 
author, year of publication, journal); country where the study was conducted including the 
World Bank economy classification and continent; study design; total number of study 
participants; median, interquartile range and age range of study participants; race; age of 
onset of oil use; type of oil use; route of administration; amount and frequency of oil used 
per day; duration of oil use; reason for oil use; pattern of clinical presentation e.g. hypoxia, 
tachypnea, mixed, other; comorbidity status - underlying swallowing dysfunction (clinical 
aspiration/ neurological deficit/ other); co-infection e.g. bacterial, viral, mycobacterial, 
fungal, other; radiological pattern e.g. fatty attenuation inside airspace opacification, 
predominant lower/posterior zone, crazy paving, ground glass opacities or nodules; 
treatment modality/modalities employed e.g. discontinuation of oil, steroids, therapeutic 
lavage, multiple approaches; proportion of children with resolution including time to clinical 
resolution and time to radiological resolution; mortality. 
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We will contact authors of the respective studies in an attempt to obtain required details 
in case there is missing information or lack of clarity with regard to methodology/outcomes. 
 
Risk of bias (quality) assessment: 
The primary reviewer (D.M) will assess the quality of studies included using the Institute 
of Health Economics (IHE) criteria for case series; the Newcastle-Ottawa Scale (NOS) for 
cohort and case-control studies; the adapted NOS for cross-sectional studies; and the 
Cochrane Collaboration Tool for Clinical Trials for observational studies and clinical trials 
respectively. These will be embedded in the standardized pre-tested data extraction form. 
(Appendix 3) 
 
Strategy for data synthesis: 
We will provide a narrative summary for included studies, particularly studies for which a 
meta-analysis is not possible. Quantitative data will be consolidated in a metanalysis. We 
will summarize continuous data using median of differences and categorical data using 
measures such as odds ratio (OR) and risk ratio (RR) for risk estimation. Summary 
measures will be pooled together according to the study design and use a random-effects 
model as it is assumed that studies may be heterogeneous. Pooled effect estimates will 
be stated with 95% confidence intervals. We will conduct a metaregression analysis to 
determine independent factors associated with exogenous lipoid pneumonia from analytic 
studies. We will to assess publication bias and provide a sensitivity analyses based on 
study quality. 
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Analysis of subgroups or subsets: 
Where data are available, we will conduct a subgroup analysis, to compare clinical-
radiologic characteristics and treatment outcomes according to, but not limited to: (a) type 
of oil (e.g. mineral, animal, vegetable or mixed), (b) age of oil use onset (e.g. neonate, 
infant, under 5 years or over 5 years old), and (c) reason for oil use (e.g. cultural or medical 
use). While subgroup analyses may be undertaken, it is not possible to specify all the 
groups in advance and additional groups may be require to be analyzed posthoc. 
 
Contact details for further information: 
Diana Marangu  
dmarangu@uonbi.ac.ke 
 
Organizational affiliation of the review: 
Department of Paediatrics and Child Health, University of Cape Town, South Africa 
 
Review team: 
Dr. Diana Marangu, Division of Pulmonology, Department of Paediatrics and Child Health, 
University of Nairobi, Kenya, and University of Cape Town, South Africa 
Dr. Diane Gray, Division of Pulmonology, Department of Paediatrics and Child Health, 
University of Cape Town, South Africa 
Dr. Aneesa Vanker, Division of Pulmonology, Department of Paediatrics and Child Health, 
University of Cape Town, South Africa 
Dr. Marco Zampoli, Division of Pulmonology, Department of Paediatrics and Child Health, 
University of Cape Town, South Africa 
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Collaborator(s): 
Dr. Komala Pillay, Division of Pathology, Department of Paediatrics and Child Health, 
University of Cape Town, South Africa 
Dr. Ebrahim Banderker, Division of Radiology, Department of Paediatrics and Child 
Health, University of Cape Town, South Africa 
 
Anticipated or actual start date: 
June 2017 
 
Anticipated completion date: 
December 2017 
 
Funding sources or sponsors: 
D.M is a recipient of the African Paediatric Fellowship Programme (APFP) scholarship 
and the Margaret McNamara Education Grant (MMEG) 2017 for Africa. However, the 
views expressed through this project do not necessarily represent the views of APFP or 
MMEG. 
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Subject index term status: 
Subject indexing assigned by CRD 
 
Subject index terms: 
Humans; Child; Neonate; Infant; Exogenous Lipoid Pneumonia; Clinical; Radiological; 
Treatment outcomes 
 
Stage of review: 
Began preliminary searches. 
 
Date of registration in PROSPERO: 30/05/2017 
Stage of review at time of this submission Started   Completed  
Preliminary searches Yes   No 
Piloting of the study selection process No   No 
Formal screening of search results against eligibility criteria No   No  
Data extraction No    No  
Risk of bias (quality) assessment No    No  
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Appendix 1: PICOTS Framework 
 Components Characteristics 
P Population Children with suspected exogenous lipoid pneumonia. 
Population characteristics:  
• Age: ≤ 18 years (< 1month; <12months; < 5years; ≥ 5years)  
• Sex 
• Region: country; World Bank classification of economies; continent 
• Setting: rural, urban; public, private 
• Comorbidity status: underlying swallowing dysfunction, other 
I Intervention/ 
Exposure 
No restriction on the intervention, if any. 
• Type of oil – mineral, animal, vegetable, mixed 
• Age of onset of oil use 
• Amount of oil 
• Frequency of oil given 
• Duration of oil use 
C Control No restriction on the control, if any. 
• Treatment option – stopping oil usage; therapeutic lavage; steroids; 
other 
O Outcomes • Clinical characteristics – predominant clinical pattern [hypoxia/ 
tachypnea/mixed; acute/chronic presentation]; caregiver reason 
for oil usage [cultural/medical; specific indication/rationale] 
• Radiological characteristics – CT pattern [fatty attenuation inside 
airspace opacification, predominant lower/posterior zone, crazy 
paving, ground glass opacities or nodules] 
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• Treatment outcome – proportion with clinical resolution; 
proportion with radiological resolution; time to clinical resolution; 
time to radiological resolution; mortality. 
T Timing  Articles will be restricted to those published between 1987 to date. This 
50 year period was arbitrarily deemed to represent data that will be 
currently relevant. 
S Setting No restriction on the setting. However, articles not published in English, 
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Appendix 2: PubMed Search Strategy - 30/05/2017 2200hrs SAST 
 Framework Search terms Number of articles 
P Population 
 












 AND (Exogenous lipoid pneumonia) P+O: 194 
T Timing 













("child"[MeSH Terms] OR Child[tw]) OR ("infant"[MeSH Terms] OR infant[tw]) AND 
("pneumonia, lipid"[MeSH Terms] OR ("pneumonia"[All Fields] AND "lipid"[All 
Fields]) OR "lipid pneumonia"[All Fields] OR ("exogenous"[All Fields] AND 
"lipoid"[All Fields] AND "pneumonia"[All Fields]) OR "exogenous lipoid 
pneumonia"[All Fields]) AND (1967:2017[dp]) AND "English"[la] 
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Appendix 3: Data Extraction Tool 
DATA EXTRACTION FORM                                                  
SCREENING                                                                                     Study ID 
                                                                                   
□ Related to exogenous lipoid pneumonia                                e.g.A001                         
□ Includes children aged < 18 years 
□ Not a letter to the editor, editorial, review article, systematic review/metanalysis 
□ Full text in English 
 
 
Study Eligible?  
□Yes        Proceed to  (final analysis ni) 
□No …… END HERE (exclude from final analysis ne) 
 
Reason For Exclusion  ________________________________________ 
 
 
FULL DATA ANALYSIS                                                                    Study ID 
                                                                                                       





First author: ________      Publication Year:    Journal: __________ 
 
 
2 Study start: Month Year  □Not documented 
 
 
3 Study end: Month Year   □Not documented 
 
 
4 Study design: □ Case report    □ Case series   □ Cross-sectional   □ Case control 
          □ Cohort    □ Experimental   □ Qualitative   □ Mixed methods 
A 
B 
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4  Intervention: ___________________________  □Not documented    □Not applicable 
 










Country World Bank Economy Classification in study year:    
□Low income country (LIC)                      □Lower middle income country (LMIC)   
□Higher middle income country (HMIC)   □High income country (HIC) 
3 Region: 
□Africa      □Asia        □Australia      □Asia       □Europe   
□North America            □South America 
 




















Comorbidity status:    
Swallowing abnormality - Number      Proportion % □ND 
 
- Clinical aspiration: Number      Proportion % □ND 
 
- Fluoroscopy confirmed: Number   Proportion % □ND 
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- Neurological risk factors: Number    Proportion % □ND 
 
- Not documented: Number      Proportion % □ND 
 





- Bacterial: Number      Proportion % □ND 
 
- Viral: Number      Proportion % □ND 
 
- Mycobacterial: Number      Proportion % □ND 
 
- Fungal: Number      Proportion % □ND 
 
- Not documented: : Number      Proportion % □ND 
 
- Other: Number      Proportion % □ND 
 
Section 3: Symptom description  
 
 
1. Cough?                          Number      Proportion % □ND  
Hotness of body?          Number      Proportion % □ND  
Fast breathing?              Number      Proportion % □ND  
Other (specify)                Number      Proportion % □ND      
               
 
2. Positive history of oil usage? Number    Proportion % □ND 
 
Type of oil? 
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- Mineral: Number      Proportion %     □ND 
- Vegetable: Number      Proportion % □ND  
- Animal: Number      Proportion %      □ND  
 
Median Age at onset of use? Years Months 
 
 
Route of administration?  
- Nose: Number      Proportion %     □ND 
- Mouth: Number      Proportion %     □ND 
- Topical: Number      Proportion %     □ND 
- Other: Number      Proportion %     □ND 
 
Median Total Amount of Oil used Daily? Millilitres       
 
Median Duration of Oil usage?  Days     Months     Years 
 
 
Reasons for oil use/Past illnesses/concerns at the time of oil use? 
- Constipation: Number      Proportion %     □ND 
- Colic: Number      Proportion %     □ND 
- Nasal stuffiness: Number      Proportion %     □ND 
- Religion: Number      Proportion %     □ND 
- Culture: Number      Proportion %     □ND 
- Other: Number      Proportion %     □ND 
 
Section 3: Examination at diagnosis  
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1. Tachypnea? Number      Proportion %     □ND 
2. 
Hypoxia? Number      Proportion %     □ND 
3. 
Hyperinflation? Number      Proportion %     □ND 
4.  
Clubbing? Number      Proportion %     □ND 
5.  
Wasting? Number      Proportion %     □ND 
Section 4: Imaging  
 
1.  
 CXR done? Number      Proportion %     □ND 
Diffuse alveolar infiltrates: Proportion %     □ND 
2.  
CT scan done?: Number      Proportion %     □ND 
Fatty attenuation inside airspace opacification: Proportion %     □ND 
Predominant lower/posterior zone: Proportion %     □ND    
Crazy paving: Proportion %     □ND 
Ground glass opacities: Proportion %     □ND 
Nodules: Proportion %     □ND 
Other: Proportion %     □ND 
 
Section 5: Treatment 
 
1.  Treatment modalities 
 
Offending agent identified and discontinued?  
Number      Proportion %     □ND 
 
Supportive [O2, respiratory Rx, control risk factors]?  
Number      Proportion %     □ND 
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Steroids?  
Number      Proportion %     □ND 
 
Therapeutic Lavage? 
Number      Proportion %     □ND 
 
Other? 
Number      Proportion %     □ND 
 
2.  Treatment outcomes 
 
Clinical resolution? 
Number      Proportion %     □ND 
 




Number      Proportion %     □ND 
 
 




Number      Proportion %     □ND 
 
Section 6: Treatment Efficacy 
 
1.  Steroids vs other?  
Odds Ratio/Risk Ratio .       □Not applicable 
 
2.  Therapeutic lavage vs other? 
Odds Ratio/Risk Ratio .       □Not applicable 
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3.  Supportive treatment [O2, respiratory Rx, control risk factors] vs other?  
Odds Ratio/Risk Ratio .       □Not applicable 
 
4.  Oil discontinuation vs other? 
Odds Ratio/Risk Ratio .       □Not applicable 
 
 
Trial Study Quality: The Cochrane Collaboration’s tool for assessing risk of bias. 
 


















































































Cohort Study Quality: The Newcastle-Ottawa Scale for Cohort Studies 
 
□Applicable      □Not applicable 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum 
of two stars can be given for Comparability  
 
Selection  
1) Representativeness of the exposed cohort  
a) truly representative of the average _______________ (describe) in the community Ø  
b) somewhat representative of the average ______________ in the community Ø  
c) selected group of users eg nurses, volunteers  
d) no description of the derivation of the cohort  
2) Selection of the non exposed cohort  
a) drawn from the same community as the exposed cohort Ø  
b) drawn from a different source  
c) no description of the derivation of the non exposed cohort  
3) Ascertainment of exposure  
a) secure record (eg surgical records) Ø  
b) structured interview Ø 
 c) written self report  
d) no description  
4) Demonstration that outcome of interest was not present at start of study  
a) yes Ø  
b) no  
 
Comparability 
 1) Comparability of cohorts on the basis of the design or analysis a) study controls for _____________ (select 
the most important factor) Ø  
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b) study controls for any additional factor Ø (This criteria could be modified to indicate specific control for a second 
important factor.)  
 
Outcome  
1) Assessment of outcome  
a) independent blind assessment Ø  
b) record linkage Ø  
c) self report  
d) no description  
2) Was follow-up long enough for outcomes to occur  
a) yes (select an adequate follow up period for outcome of interest) Ø  
b) no  
3) Adequacy of follow up of cohorts 
 a) complete follow up - all subjects accounted for Ø  
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an adequate %) follow 
up, or description provided of those lost) Ø c) follow up rate < ____% (select an adequate %) and no description 
of those lost d) no statement 
 
Case Control Study Quality: The Newcastle-Ottawa Scale for Case Control Studies 
 
□Applicable      □Not applicable 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum 
of two stars can be given for Comparability.  
 
Selection 
1) Is the case definition adequate?  
a) yes, with independent validation Ø  
b) yes, eg record linkage or based on self reports  
c) no description  
2) Representativeness of the cases  
a) consecutive or obviously representative series of cases Ø  
b) potential for selection biases or not stated  
3) Selection of Controls  
a) community controls Ø  
b) hospital controls  
c) no description 
4) Definition of Controls  
a) no history of disease (endpoint) Ø 
 b) no description of source  
 
Comparability  
1) Comparability of cases and controls on the basis of the design or analysis  
a) study controls for _______________ (Select the most important factor.) Ø  
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b) study controls for any additional factor Ø (This criteria could be modified to indicate specific control for a second 
important factor.)  
 
Exposure  
1) Ascertainment of exposure  
a) secure record (eg surgical records) Ø  
b) structured interview where blind to case/control status Ø  
c) interview not blinded to case/control status  
d) written self report or medical record only  
e) no description  
2) Same method of ascertainment for cases and controls  
a) yes Ø  
b) no  
3) Non-Response rate 
 a) same rate for both groups Ø  
b) non respondents described  
c) rate different and no designation NEWCASTLE - OTTAWA QUALITY 
 
Cross-sectional Study Quality: The Newcastle-Ottawa Scale (Customized) 
 
□Applicable      □Not applicable 
Selection: (Maximum 5 stars) 
1) Representativeness of the sample: 
              a) Truly representative of the average in the target population. * (all subjects or random sampling) 
              b) Somewhat representative of the average in the target population. * (non-random sampling) 
              c) Selected group of users. 
              d) No description of the sampling strategy. 
2) Sample size: 
              a) Justified and satisfactory. * 
              b) Not justified. 
3) Non-respondents: 
a) Comparability between respondents and non-respondents characteristics is established, and the response 
rate is satisfactory. * 
              b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents 
is unsatisfactory. 
              c) No description of the response rate or the characteristics of the responders and the non-responders. 
4) Ascertainment of the exposure (risk factor): 
               a) Validated measurement tool. ** 
               b) Non-validated measurement tool, but the tool is available or described.*  
               c) No description of the measurement tool. 
  
Comparability: (Maximum 2 stars) 
1) The subjects in different outcome groups are comparable, based on the study design or analysis. 
Confounding factors are controlled. 
                a) The study controls for the most important factor (select one). * 
                b) The study control for any additional factor. * 
30th May 2017 
 
Outcome: (Maximum 3 stars) 
1) Assessment of the outcome: 
                a) Independent blind assessment. ** 
                b) Record linkage. ** 
                c) Self report.  * 
                d) No description. 
2) Statistical test: 
                a) The statistical test used to analyze the data is clearly described and appropriate, and the 
measurement of the association is presented, including confidence intervals and the probability level (p value). * 
                b) The statistical test is not appropriate, not described or incomplete. 
 
Case Series Study Quality: The Institute of Health Economics 
 
□Applicable      □Not applicable 
Study objective 




2. Was the study conducted prospectively? Yes   ☐ 
Unclear  ☐ 
No ☐ 
3. Were the cases collected in more than one centre?  Yes   ☐ 
Unclear  ☐ 
No ☐ 
4. Were patients recruited consecutively?  Yes   ☐ 
Unclear  ☐ 
No ☐ 
Study population  
5.  Were the characteristics of the patients included in the study 
described? 
Yes   ☐ 
Partial ☐ 
No ☐ 
6.  Were the eligibility criteria (i.e. inclusion and exclusion criteria) for 
entry into the study clearly stated? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
7.  Did patients enter the study at a similar point in the disease? 
 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
30th May 2017 
Intervention and co-intervention 
8.  Was the intervention of interest clearly described? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
9.  Were additional interventions (co-interventions) clearly described? 
 




10.  Were relevant outcome measures established a priori? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
11. Were outcome assessors blinded to the intervention that patients 
received? 
 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
12.  Were the relevant outcomes measured using appropriate 
objective/subjective methods? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
13. Were the relevant outcome measures made before and after the 
intervention? 
 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
Statistical analysis 
14. Were the statistical tests used to assess the relevant outcomes 
appropriate? 
 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
Results and conclusions 
15. Was follow-up long enough for important events and outcomes to 
occur?  
 
Yes   ☐ 
Unclear ☐ 
No ☐ 
16. Were losses to follow-up reported? 
 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
17. Did the study provided estimates of random variability in the data 
analysis of relevant outcomes? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
18. Were the adverse events reported? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
30th May 2017 





Competing interests and sources of support 
20. Were both competing interests and sources of support for the study 
reported? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
*Note: Assessor(s) may decide to remove from the checklist the items that are not applicable to their project. 
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other frameworks. In: Chang SM, Matchar DB, Smetana GW, Umscheid CA, editors. 
Methods guide for medical test reviews. Rockville (MD): Agency for healthcare research 
and quality (US); 2012. 
2. Institute of Health Economics (IHE). Quality Appraisal of Case Series Studies 
























% Male Type of oil (amount, 
frequency) 
Age range at 











India, Chandigarh Case 
report 




daily melted ghee) 
30 
Chronic [14] 







India, Pondicherry Case 
series 









































USA, Pittsburgh Case 
report 





































Culture - force feeding 





























Culture - force feeding 
ghee, instilled nasally for 





























Culture - butter fat as a 
nutritional supplement; 
olive oil instilled nasally 



























Culture - force feeding 
ghee in 21/24 patients 
(3/24 had severe 
















































Medical - treatment of 
constipation 
































































































Culture - force feeding or 




















































































































































Culture - nasal instillation 



































Culture - for normal 
bowel habits, treat 
coughs and cold and 



























Medical - given as a 
laxative 












































Medical - given orally for 
constipation 
(Neuro-developmental 
delay with seizure 
disorder; Swallowing 


































Culture - given orally: 
only olive oil 9/16; olive 




































olive oil plus turtle oil 






CP, vascular ring, Down 
Syndrome, Down 
Syndrome + congenital 
cardiomyopathy; 8/16 - 











































Culture - 5ml olive oil for 
constipation 
(GOR and poor 
esophageal motlity 




































































Culture - 20/25 positive 


















































































Culture - shark liver oil 
given orally 
(all involuntarily ingested 
the oil; 2/8 post 
encephalitis, 1/8 Lennox 
Gestaut; 1/8 GOR; 1/8 


























































Culture - given 200ml 
daily of olive oil for 
fussiness; for nasal 
congestion 
(Child 1: silent aspiration 
with thin liquids on 
contrast swallow;  
Child 2 - discoordinated 












   
 
swallow and poor 


























Cultural – oil instillation 
(2/9 -perinatal brain 































Medical - treatment for 
chronic constipation 































Culture - force feeding of 



































































Medical - treatment of 
constipation 23/28 and 
complicated ascariasis 
5/28 (infancy 22/28; 
































  (10 peeled off 
squalene capsules 
daily, each capsule 
0.5ml) 
[90] (forceful oil 



























Culture - sesame oil 



















































Culture - fed ghee or 


















































Medical - for constipation 



































Medical - ketogenic diet 
consisting of lipid oil 
mixtures for seizure 
control (intractable 








congenital CMV; no 
cough/ swallowing reflex, 






























Behavioral - drank large 
amounts of olive oil when 
frustrated  






























Culture - orally 
administered castor oil 
for constipation  



























































ND – not documented; GOR – gastro-esophageal reflux. 
Diagnostic accuracy of exogenous lipoid pneumonia: 1 – (Suspected) suggestive clinical history without histological assessment; 2 – (Possible) suggestive clinical history with non 
specific histological findings e.g. foamy macrophages/granulomas on BAL or lung biopsy but no mention of lipid staining; 3 – (Probable) suggestive clinical history with positive intracellular 
lipid staining of macrophages e.g. Oil Red O positive on BAL or lung biopsy but no mention of extracellular lipid; 4 – (Confirmed) suggestive clinical history with positive intracellular lipid 
staining macrophages in addition to being macroscopically oily or the presence of extracellular lipid in BAL or frozen section of lung biopsy; 5 – Confirmed+) suggestive clinical history 
with positive staining of both intracellular and extracellular lipid in BAL/frozen section lung biopsy plus additional BAL lipid analysis e.g. gas chromatography/mass spectrometry 
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first author, study type 
(participants) 





ND CXR (dense opacity in the RUL and 
RML); CT (mass in posterior 
mediastinum); Lung biopsy; 
Autopsy) 
Surgical resection (right 
pneumonectomy) 





Case series (12) 
ND CXR in 12/12 (diffuse pattern more 
common in the RUL and RML); No 
CT; 1/12 BAL; 2/12 lung biopsies 
Supportive treatment; 






Case series (4) 
Recurrent infections in 
1 child (microbiology 
ND) 
CXR in 4/4 (diffuse bilateral 
infiltrates); CT in 2/4 (predominant 
posterior basal densities, negative 
HU); 4/4 BAL; 1/4 lung biopsies; 2 
autopsies 
4/4 supportive treatment; 
4/4 steroids (details not 
specified); 4/4 antibiotics; 
4/4 therapeutic lavage 
Post aspiration; post 
supportive treatment; 
post discharge 
2/4 clinical resolution 
2/4 deaths - 30 days post 
discharge, and 3 months 
post discharge due to 
recurrent LRTIs 
respectively 
No radiological resolution 
at 4 and 6 months post 
discharge - CT densities 





Peritoneal exudate - 
Enterococcus, E.coli, 
Klebsiella, Coagulase 
CXR (bilateral alveolar and 
interstitial infiltrates); no CT; 
Supportive treatment – 
antibiotics; 
Colonostomy  
post admission day; 
post colonostomy day 
 
Died at age 5 months - 1 






Autopsy; Gas chromatography of 




ND CXR (diffuse bilateral infiltrates); no 
CT 
ND ND ND 
06 1991 
Annobil(20) 
Case series (10) 
M. fortuitum on open 
lung biopsy specimen; 
drug susceptibility 
details ND 
CXR (perihilar infiltration; RUL and 
RML consolidation; bilateral 
extensive consolidation involving 
multiple lobes of both lungs); 3/10 
CT (no fatty attenuation); BAL 8/10; 
Lung biopsy 2/10; 1 autopsy. 
Supportive treatment 
(10/10) – antibiotics and 
antifungals; Steroids 
(10/10) - Prednisone at 
2mg/kg/day for 2weeks to 
14 months; Surgical 
resection (2/10) - 
lobectomies 
ND Clinical resolution (7/10);  
Radiological resolution 
(7/10) 
Death (1/10) – extensive 
M. fortuitum infection 
07 1991 
Hugosson(21) 
Case series (9) 
TB treatment had been 
started for one child 
prior to clinical 
presentation 
CXR (9/9) - diffuse bilateral 
consolidation medial posterior 
areas and perihilar distribution; CT 
(8/9) - areas of consolidation 
involving specific segments; Lung 
biopsy (4/9); FNA biopsy (6/9) 
Supportive treatment (9/9) 
– antibiotics (9/9), anti-
TBs (1/9);  
Steroids (9/9) – details not 
specified; Surgical 
resection (4/9) – affected 
parts  
ND Radiological resolution 




Case series (24) 
Negative 
(bacterial, fungal and 
AFBs tested) 
CXR (2/24) - bilateral multilobar 
consolidation (12/24), bilateral peri-
hilar infiltrates (5/24), right perihilar 
infiltrates (5/24), unilateral right 
Supportive treatment 
(24/24); Steroids (24/24) – 
not specified; Therapeutic 
lavage (24/24) 
Post-bronchoscopy Clinical resolution (24/24);  
No radiological resolution - 
CXR infiltrates still present 
12 
 
multilobar consolidation (2/24); No 
CT; BAL (22/24); Lung biopsy (2/24) 
1-month post 




among medical pediatric 
admissions between April 
1989-1990 of a hx of oil 
instillation 
(800/1090=73.4%) 
ND CXR - 176 patients had positive 
CXRs i.e. 176/800=22% and had a 
positive hx of oil ingestion: RUL 
opacities -40%, RML opacities -
44%, generalized bilateral patchy 
opacities - 30%, bilateral midzone 
involvement - 52%; No CTs 




Negative CXR - Diffuse bilateral perihilar and 
RUL airspace opacification; No CT 
Supportive treatment – 
oxygen, antibiotics 
ND Followed up to age 5 years 
Clinical resolution (4.7 
years); No radiological 
resolution (mild residual 
bilateral interstitial 





Negative (bacterial and 
fungal cultures) 
CXR – bilateral infiltrates; No CT; 
Autopsy 
Supportive treatment – 
oxygen, conventional 
ventilation 
Post admission No clinical or radiological 
resolution 





M. smegmatis on open 
lung biopsy specimen 
susceptible to 
imipenem, tetracycline, 
CXR - dense opacification lower 
lobes, RML and lingula; No CT; 
gastric and bronchial washings; 
open lung biopsy 
Supportive treatment – 
antibiotics [amikacin 
stopped after 15/7 due to 
renal toxicity; doxycycline 
Post admission** After starting steroids - 
prompt fever resolution 
and mild tachypnea at 







3/12; ciprofloxacin 1 year]; 
Prednisone 60mg daily for 
14/7 then tapered 
Lost to follow-up  
Clinical resolution at 1-
year post-admission (well 
and had regained baseline 
developmental function) 
No radiological resolution 














(ZN and silver stain) 
CXR (4/4) – 3/4 bilateral 
consolidation; 1/4 LLL collapse 
consolidation & bronchiectasis; No 
CTs; Lung biopsy 1/4 
Supportive treatment (4/4) 
– antibiotics; Surgical 
resection (3/4) - 
lobectomies 
Post-surgery Clinical resolution (2/4) 
Radiological resolution 
(2/4) 
Bronchiectasis in 2 
patients as sequelae - one 
of whom died 
Deaths (2/4) - died 11th 
post op day, and year 2 
post lobectomy from 








CXR - bibasal chronic lung 
changes; No CTs; Lung biopsy 
Educated caregivers to 
stop giving oil 
Post-stopping oil Clinical resolution after 1 
year after stopping oil 












ND CXR – hyperinflation, bilateral 
infiltrates in a batwing distribution 
more prominent in the mid and 
lower lung fields; CT - bilateral 
consolidations with air 
bronchograms in the mid and lower 
lung fields more prominent on the 
left side; FNA biopsy 
Supportive treatment 
(antibiotics); Steroids – 
not specified; Chest 
physiotherapy 
Post-treatment Clinical resolution 3 
months post treatment 
No radiological resolution - 
CXR at 20 months showed 
incomplete clearing of 
infiltrates in the posterior 
segment of the LLL 
Alive at 4 months and 20 













CXR (2/2) - RUL expansile 
pneumonia and patchy perihilar 
consolidation; homogenous 
consolidation right lung, perihilar 
and midzones of the left with air 
bronchograms; CT (1/2) - Bilateral 
consolidations with air 
bronchograms in the mid and lower 
lung fields, no cavitations, no fat 
densities; FNA biopsy (1/2) 
Supportive treatment (2/2) 
- antibiotics; Steroids (1/2) 
Post-admission No deaths;  
Follow-up details ND 
*Concerns about 








ND CXR -  
Homogenous alveolar consolidation 
of the right lung; CT -  
consolidation contained low fat 
densities (-30 to -150 HU) mixed 
with soft tissue densities in the R 
Supportive treatment – 
oxygen; Educated 
caregivers to stop oil; 
Therapeutic lavage – 
whole lung lavage 30 
Post-admission; Post-
therapeutic lavage 
Clinical resolution – 10 
days post therapeutic 
lavage (oxygen 
saturations normalized 3 
weeks post admission) 
15 
 
and non-specific acinar infiltrates in 
the posterior segment of the LLL; 
BAL 
aliquots of 20ml sterile 
saline 
Radiological resolution - 
almost clearing 40 days 
post therapeutic lavage 
Alive 40 days post lavage, 



















(Bacterial, Fungal and 
AFBs tested) 
CXR (5/5) - Diffuse perihilar 
infiltrates; No CT 
Supportive therapy (5/5) – 
antibiotics; Steroids (5/5) - 
Prednisolone at 
2mg/kg/day;  
Educated caregivers to 
stop oil; physiotherapy 
twice daily 
Duration post therapy 
day 
Clinical resolution (5/5) – 
varied: 2/5 – completely 
recovered after 1 month; 
1/5 – recovered after 2 
months                         2/5 
– recovered after 5 months 
of therapy; 
Radiological resolution ND 
* Steroid use in treatment 
seems to improve clinical 









ND CXR - Expansile RUL pneumonia; 
CT - Homogenous (tumor like) 
opacification in the RUL: 30 - 40 HU.  
Supportive treatment – 
antibiotics; Steroids - 
Prednisolone (2 mglkg per 
Time at starting 
steroids 
Followed for 2 months 
after steroids, antibiotics 








*follow up CT chest – more 
infiltrates… 
day) for 2 months 
thereafter continued for 
several months (duration 
not specified) 
treatment - thoracic 
consult recommended to 
continue treatment for 











ND CXR - Diffuse infiltrates;  
CT - expanded appearance;  
BAL including quantifying the 
number of activated T lymphocytes 
and alveolar macrophages: 
CD3CD8 predominance 
Supportive therapy; 
Steroids NOT used 
because noted declining 
levels of BAL 
lymphocytes; Educated 
caregivers to stop oil; 
Therapeutic lavage - 4 
lavages in total: 
admission, 6 months, 12 
months and 18 months 
Post-diagnosis day Clinical resolution  
No radiological resolution - 
CXR – 1yr after: reduced 
lung consolidation 
Perfusion scan – 1 yr after: 
unchanged (perfusion 
defects LLL and RUL) 
 
 







Negative CXR – RUL anterior and posterior 
segment dense alveolar infiltrate; 
CT - dense infiltrate RUL anterior + 
posterior  
segments; BAL; and BAL mass 
spectrometry identical to oil patient 
used 
Supportive therapy – 
antibiotics; Educated 
caregivers to stop oil 
Post-stopping oil day Clinical resolution 
No radiological resolution - 
CXR 1 and 3 month after 
stopping oil – no change; 
CT chest – RUL anterior 
and posterior segments at 
1month after stopping oil 
22 1999 
Furuya(36) 
Case series (16) 
 
ND CXR (16/16) - Right lung always 
involved; CT (8/16) - Perihilar and 
posterior dependent lung portions 
[nonspecific], 2/8 CTs fatty 
Supportive therapy 
(16/16) – antibiotics 11/16, 
bronchodilators 10/16; 
 Clinical resolution (14/16) 










attenuation; BAL (15/16); Lung 
biopsy (1/16) 
Steroids (6/16); Surgical 




Death (1/16) – autopsy 
done 
Radiological resolution ND 
*Although predominantly 
olive oil, two were mixed - 
almond and the second 








respiratory viral panel 
negative) 
CXR - Diffuse consolidation RUL, 
RLL and LLL; No CT 
Supportive therapy – 
oxygen, antibiotics 
Post-admission day Clinical resolution – 7 days 
post admission 
Radiological resolution ND 







(Blood cultures, viral 
NPAs – negative) 
CXR - Bilateral airspace disease 
with relative sparing of the upper 
lobes; CT - suggested lipid within 
airspace opacification 
Supportive therapy – 
oxygen (20 months), 
antibiotics;  
Post admission day Clinical resolution – 600 
days post admission 








ND CXR (25/25) - Consolidation 23/25, 
atelectasis 18/25. Predominant lobe 
involved = RLL 20/25; No CTs 
Supportive therapy (8/25) 
– antibiotics; Educate 
caregivers to stop oil 
None Clinical resolution ND 
Radiological resolution ND 
Period of follow up was 42 












ND CXR (8/8) - Bilateral, parahilar 
predominantly right lung; CTs (7/8) 
- Dense consolidation surrounded 
by GGOs with geographic lobular 
distribution-7/7 1/7-fatty 
attenuation; crazy paving 3/7; 7/7 
central posterior zones affected. 
Supportive therapy (8/8) – 
antibiotics; Educate 
caregivers to stop oil (8/8) 
Post-admission day Clinical resolution ND 
No radiological resolution - 
improvement on follow up 
CXR mean 5.4 months 











ND specifically for 
children with lipoid 
pneumonia 
ND ND Post-administration of 
the ketogenic diet 
Followed up for 12 months 
3/10 diagnosed with ELP 
within first 4 weeks 
6/10 diagnosed with ELP 
after 4 weeks 
1/10 diagnosed both 
before and after 4 weeks 
1/10 death within 2 months 










positive on BAL of child 
1, fungi and viruses 
negative; Child 2: 
negative AFBs 
CXRs (2/2) – Child 1 bilateral 
perihilar infiltrates with mild 
hyperinflation and RUL atelectasis; 
Child 2: RUL, RLL and LUL 
consolidation; CTs (1/2) – Child 1: 
Bilateral consolidation, fatty 
attenuation, crazy paving; BAL (1/2) 
Supportive therapy (2/2) – 
antibiotics (2/2), oxygen 
(1/2), CPAP (1/2); 
Educated caregivers to 
stop giving oil (2/2)  
Post-discharge day Clinical resolution 7 
months post discharge for 
child one, and at discharge 
for child two. 
No radiological resolution 




M.fortuitum/ CXR/CT ND; Lung biopsy (5/9); 
Autopsy (4/9) 
Surgical resection (4/9) – 
RUL resection 
None Clinical resolution (3/9) 





chelonei in 1/5 BAL 
cultures 
Deaths (5/9) 























Negative CXR (17/17) - 
bronchitis/peribronchitis and patchy 
infiltrates in the middle;  
CT (17/17) - Air space consolidation 
(17); fatty attenuation (12)  [-21 to -
90 HU]; ground glass attenuation 
(10) – 4/10 focal,  3/10 crazy paving 
pattern; predominant 
posterior/lower regions of the lung; 
1/17 – confluent airspace nodules in 
the periphery of a consolidation; NO 
pleural effusion, LN enlargement or 
other chest abnormality; 8/17 – 
central, 9/17 both central and 
peripheral; Lower lobes abnormal in 
ALL (17/17); Severe dx – RLL 15/17 
, RUL 14/17 and LLL 13/17; 14/17 – 
predominant air space 
consolidation; 3/17 predominant 
crazy paving pattern; 17/17 – 
bilateral abnormality on CT, 
predominant right 10/17, 
Supportive therapy 
(17/17) – antibiotics 17/17, 
conventional ventilation 
2/17 
ND Follow-up data available 
for 12/17 
 
1/17 - deteriorated on 




predominant left 1/17, both 6/17; 











M.fortuitum CXR – both lower lobes; CT - 
Cavitating consolidation of all 
segments of the LLL and inferior 
segment of the lingual, RML and 
RLL; sputum;  
Supportive therapy – 
antibiotics. 
M.fortuitum regimen total 
12 months of treatment: 
RHE for 2/12 then 
Clarithromycin + Amikacin 
thrice weekly – Amikacin 
stopped after 2/12; the 
rest continued for another 
10 months  
Post-discharge day Clinical resolution 6 
months post discharge 
(asymptomatic and gained 
weight) 
 
No radiological resolution - 
CXR near complete 
clearance of infiltrates 6 












ZN, gram, fungal, 
bacterial cultures) 
CXR - Extensive bilateral 
consolidation RUL, RML, lower 
lobes;  
CT - Extensive bilateral 
consolidation RUL, RML, lower 
lobes; BAL; Lung biopsy 
Supportive therapy – 
oxygen, CPAP and 
antibiotics; Steroids - 
Prednisolone at 
2mg/kg/day for 3 weeks 
tapered over 9 weeks; 
inhaled beclomethasone 
250mcg q12h for 6 
months 
Post-admission day Clinical resolution 6 
months post admission 
 
Radiological resolution not 
complete - radiological 
improvement on CXR at 6 







ND CXR (27/28) - Consolidation 23/28, 
perihilar infiltrates 13/28;  
CT (28/28) - Consolidation and 
bronchograms 24/28, decreased 
Supportive therapy 
(28/28) – antibiotics; 
Steroids (2/28) – details 




Clinical resolution (20/28) 
- 20/22 that had 















attenuation in areas of consolidation 
16/28, GGOs 3/28, crazy paving 
1/28; 28 BAL  
lung-lavages (22/28) – 
multiple mean 9.6 
 
Therapeutic lavage done 
in 22 (of these 2 had add 
on steroids) - Lavage – 
clearance of mineral oil 
from lungs AND 
prevention of fibrosis 




Radiological resolution - 
18/20 that were 
asymptomatic after 
therapeutic lavage had 
CTs normalized 
 
Follow-up period of 24 
months: 22/28 – 
therapeutic BAL (20 of the 
22, asymptomatic after 
treatment; 18 of 20 CTs 
normalized); 2/28 – 
steroids (and multiple 









ND CXR - Diffuse consolidation 
bilaterally; CT - Extensive bilateral 
consolidation; heterogenous 
attenuation including fat-like 
densities within consolidations; 
BAL; Lung biopsy 
Supportive therapy – 
oxygen and antibiotics; 
Steroids – 
Dexamethasone IV 
0.3mg/kg for 2/52, tapered 
with oral prednisolone; 
Post-admission day No clinical resolution  
No radiological resolution 
Persistent clinical and 
radiological features 3 
months of discharge 
- 2-week follow-up partial 








Educated caregivers to 
stop giving oil 
improvement; Discharged 
from hospital after 3 
months; Received 












CXRs (69/69) - Radiographic 
features suggestive of oil aspiration 
(persistent collapse consolidation, 
RUZ collapse consolidation in 
infants, perihilar dense infiltrates 
etc.; No CTs 
Supportive therapy 





into 3 categories) 
<24hrs (25/69), 2-7 
days (23/69); >7 days 
(21/69) 
Clinical resolution ND 
Radiological resolution ND 
Deaths: 3/7 who needed 
mechanical ventilation 
died 










Klebsiella, Mixed flora 
(7/41 BAL cultures 
done) - cannot separate 
findings for patients 
with lipoid pneumonia 
CXRs (41) and CTs (23) – cannot 
separate findings for patients with 
lipoid pneumonia;  
Supportive therapy (9/9) – 
antibiotics. 
ND Clinical resolution/ 
improvement: 6 







ND CXR/CT – ND;  
BAL (8/8) – gas chromatography 
done and mass spectrometry 
compared to home-made ghee and 
olive oil given to the children 













M. fortuitum on gastric 
aspirates, central 
venous catheter blood 
culture and 2 
endotracheal cultures; 
Candida glabrata on 1st 
BAL not considered a 
true pathogen (AFBs 
and bacterial culture 
negative)  
CXR - Bilateral consolidations;  
CT - Consolidations in the RUL, 
RLL and LLL with possible necrosis; 
BAL 
Supportive therapy – 









Post-admission day Clinical resolution – after 
42 days (6/52) 
hospitalization  
 








ND CXR - Bilateral apical infiltrates; CT 
- Extensive consolidation and 
geographical GGOs bilaterally; BAL 
Supportive treatment – 
oxygen, antibiotics. 
Steroids - Prednisone at 
1mg/kg/day for 30 days. 
 
Post-admission day Clinical resolution – 30 
days post admission 
No radiological resolution - 
partial decrease in 
parenchymal lesion  
No death by follow-up at 










(blood culture; viral and 
atypical organism 
serology; TB excluded; 
BAL negative for 
bacteria and fungi) 
CXR and CT - Diffuse parenchymal 
infiltration of the right lung, 
atelectasis left dorsal basal lung 
segment, enlarged pretracheal and 
hilar LN; BAL 
Supportive therapy – 
oxygen, antibiotics. 
Steroids - at 1-2mg/kg/day 
initially parenterally, then 
orally.  
Immunoglobulins. 
Stopped ketogenic diet. 
Inhalational treatment. 
Time after starting 
steroids 
Clinical resolution – 42 
days after starting steroids 
 
No radiological resolution - 
CXR showed significant 
improvement in the lungs 













(both IgM and Ig G) 





TST negative.  
CXR - RUL + RLL infiltrates; 
CT - Airspace consolidation 
posterior segment RUL and apical 
segment RLL characterized by very 
low density similar to fat tissue; BAL 
Supportive therapy – 
antibiotics. 
 
Therapeutic whole lung 
lavage. 




Clinical resolution 30 days 
post therapeutic lung 
lavage. 
Radiological resolution 60 
days post therapeutic lung 
lavage. 








ND CXR - Bilateral fluffy infiltrates 
upper and mid zones;  
No CT; No BAL 
Supportive therapy – 
oxygen, antibiotics, IV 
fluids. 
Steroids - 
Dexamethasone IV (no 
dose provided) 















CXR - Bilateral multifocal increased 
opacities;  
CT - Diffuse bilateral GGOs, smooth 
interstitial thickening, bilateral crazy 
paving pattern predominantly 
posterior and lower zones; BAL 
Supportive therapy. 
Educated caregivers to 
stop giving oil. 




Length of follow-up 
implied in the text was 10 
hospital days. 
AFB – acid fast bacilli; BAL – bronchoalveolar lavage; CT – chest computed tomograph; CXR – plain chest radiograph;   FNA – final needle aspirate; GGO – ground glass opacification; 
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